Identification, Structure–Activity Relationship (SAR), and Biological Evaluation of New Chemical Series as Malaria Parasite PfGCN5 Bromodomain Inhibitors Authors: Pedro Martin-Acosta, Abbas H. K. Al Temimi, Luma Godoy Magalhaes, Juan Salamanca-Viloria, Jose Ignacio Martin Hernando, Ana I. Villegas, Virginia Franco Hidalgo, Joel McMillan, Andrew Plater, Mark Anderson, Raquel Gabarro, Felix Calderon, Maria Santos Martinez-Martinez, Emiliana D’Oria, Jair L. Siqueira-Neto, Barbara Forte, Esther Fernandez, Elizabeth A. Winzeler, Ana Lisa Valenciano, Beatriz Baragaña, Sonia Moliner-Cubel, Francisco Javier Gamo Published: 2026 ABSTRACT Despite considerable progress in prevention, treatment, and eradication efforts, malaria continues to impose a significant public health and socioeconomic burden for many countries around the globe. With the effectiveness of current treatment options partially or totally compromised due to resistance, the validation of new targets and the development of new drugs that can reach the demanding standards required for the treatment of this disease represent an urgent and considerable challenge. Herein, we report the evaluation of approximately 48 200-compound library selected from the GSK collection against PfGCN5. From the 6 initial hits with pIC50 > 5, two compounds were progressed for further in vitro profiling and optimization. Computational and medicinal chemistry efforts delivered significantly improved compounds 21h and 41d with pIC50 within the submicromolar range (pIC50 6.6 and 7.0, respectively), but unfortunately, the lead compounds did not show potent in vitro antiparasitic activity. Although further studies are still necessary, our initial data suggest that targeting PfGCN5 to develop new antimalarial compounds might be challenging. Introduction Malaria remains a significant global health challenge. Despite considerable progress in prevention, treatment, and control efforts, this disease continues to impose a heavy burden on public health and socioeconomic development, particularly in regions where the parasites responsible for the disease are endemic. Five species of the Plasmodium genus are known to be responsible for human infections, P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. Among them, P. falciparum causes the most severe cases of the disease, especially in children under the age of five, who are among the most vulnerable groups. Despite P. vivax being less virulent, it still poses an important threat. Its milder symptoms favor propagation, while undetectable hypnozoites and relapses complicate control and eradication efforts. Historically, the main treatment for malaria relied heavily on traditional drugs, but their effectiveness has now been completely or partially compromised because of resistance. Artemisinin-based combination therapies (ACTs), unlike other drugs, remain relatively effective against uncomplicated malaria infections. However, the emergence and spread of drug resistance to various partner components (lumefantrine, artemether, etc.) have started to challenge the efficacy of these treatments in many regions, highlighting the need for alternative approaches. The emergence of insecticide resistance affecting vector control and drug-resistant strains of Plasmodium, together with limitations in existing treatment options, accentuates the urgent need for innovative therapeutic strategies. Over the past decades, partnerships between public, private, academic, and philanthropic sectors , have been directed toward the discovery and development of new antimalarial treatments and the identification of novel targets. , The characterization and validation of new targets, the elevated costs and low success rate in the progression of new drugs, together with the advances in computational techniques have driven a shift from more traditional high-throughput phenotypic screening toward target-based approaches. This approach facilitates target selection and validation, hit optimization, and progression among other aspects. Consortia as MalDA (Malaria Drug Accelerator) have coordinated efforts to avoid duplicities, prioritize progressable targets, and accelerate the discovery and development of novel molecules able to meet the demanding target product profile required for new antimalarial drugs. These endeavors have yielded valuable insights into the biology of the parasite and the mechanisms underlying its survival and pathogenesis and have identified new molecular targets essential for the discovery and rational design of next-generation antimalarial drugs, such as cytoplasmic isoleucine–tRNA ligase (cIRS) and farnesyl pyrophosphate–geranylgeranyl diphosphate synthase (FPPS–GGPPS). One of the new targets that has been explored is the histone acetyltransferase (HAT), GCN5 (General Control Nonrepressed Protein 5). The complex lifecycle of apicomplexan parasites requires an intricate regulation of transcription as they interact with the host and mosquito vector. HAT enzymes are evolutionarily conserved large multimeric protein complexes such as the 20-subunits SAGA (Spt-Ada-Gcn5 acetyltransferase) complex, which bears GCN5 as part of the HAT catalytic core (GCN5, ADA2, ADA3, and Sgf29). Interestingly, the HAT module in parasites such as P. falciparum might be significantly divergent from the HAT in humans or yeasts SAGA complexes. Rather than the conserved Sgf29 Tudor reader found in many eukaryotic SAGA complexes, P. falciparum‘s HAT complex contains an unconventional reader with four PHD-finger domains. GCN5 plays a crucial role in regulating gene expression in Plasmodium parasites by catalyzing the acetylation of histone protein 3 at lysines 9 and 14 (H3K9Ac and H3K14Ac). This modification modulates the chromatin structure and accessibility, thereby triggering the expression of targeted genes. Recent studies have highlighted the importance of GCN5 in the transcriptional regulation of genes involved in Plasmodium development, antigenic variation, erythrocyte invasion, and virulence. , GCN5 was experimentally identified through piggyBac transposon-saturation mutagenesis as being likely essential in P. falciparum as well as in its murine orthologue. Disruption of GCN5 activity has been shown to impair parasite growth and development, suggesting that inhibitors targeting this enzyme could exhibit potent asexual blood-stage antimalarial activity. Moreover, the conservation of GCN5 across different Plasmodium species and its expression across all stages of the lifecycle further supports its potential as a broad-spectrum antimalarial target making it attractive for drug discovery. In addition, presumably selective pharmacological inhibition of the human bromodomains PCAF/GCN5 has been shown to be insufficient to disrupt their function, suggesting that a PfGCN5 inhibitor might have a wider selectivity window, making it a promising target in terms of safety. Despite all of this, further research is still needed to identify and characterize new molecules with potent activity against PfGCN5 that translates into submicromolar parasite growth inhibition. Several compounds are known to modulate PfGCN5′s activity (Figure ). Cui et al. (2008) reported that Anacardic acid (AA) reduces acetylation of histone 3 at K9 and K14 in a dose–response manner and inhibits recombinant PfGCN5 with a pIC50 of 4.6. This molecule also inhibits the growth of chloroquine-sensitive and -resistant parasite strains with a pIC50 of approximately 4.5. More recently, Chen et al. (2016) developed a microfluid-based drug-screening system and identified known HAT inhibitors such as Butyrolactone 3 (MB-3, pIC50 3.9), CPTH-2 (pIC50 3.9), and Curcumin (pIC50 5.5) as inhibitors of PfGCN5. In the same year, Moustakim and coworkers developed the first nanomolar, selective PCAF/GCN5 bromodomain inhibitor L-45 (or L-Moses) and presented a cocrystal structure of PfGCN5 with the inhibitor. Other compounds such as the natural benzoquinone Embelin (Srivastava et al. 2014) have been reported as specific inhibitors for the PCAF/GCN5 HAT family, decreasing H3K9Ac levels in the parasite and inhibiting parasitic growth at low micromolar range (pIC50 5.0) which points to a possible PfGCN5-mediated inhibition. In 2017, the same laboratory computationally identified multiple potential PfGCN5 inhibitors and experimentally evaluated C14 in vitro and in vivo as an inhibitor of PfGCN5 demonstrating fairly potent antimalarial activity. However, C14 reduced H3K9 acetylation only at 1 μM, while its whole-cell potency against parasites is ∼0.2 μM, raising the possibility that the observed antiplasmodial activity may involve targets other than PfGCN5. With the possible exception of C14, none of these molecules are expected to act as specific inhibitors of PfGCN5 over its human orthologue; rather, most are broad-spectrum HAT inhibitors or human-targeted probes that happen to cross-react with the parasite enzyme. Anacardic acid, MB-3, curcumin, CPTH-2, and embelin all inhibit human HATs (p300, PCAF, or GCN5), and L-45, although selective for the human PCAF/GCN5 bromodomain, also engages PfGCN5 due to the structural homology between the human and parasite bromodomains. Only C14 was explicitly designed to exploit active-site differences between PfGCN5 and hGCN5, and while computational studies predicted species-selective inhibition, experimental evidence confirming PfGCN5 selectivity at the target level is still lacking. (A) Known reported inhibitors of PfGCN5 targeting HAT catalytic domain. (B) Reported PfGCN5 bromodomain inhibitor. (C) Potential GCN5 inhibitor with reported Pf(3D7) ABS activity. In this work, we provide an overview of our recent efforts to discover and develop novel PfGCN5 bromodomain inhibitors. We discuss the structure–activity relationship of our compounds and the correlation between enzymatic versus asexual blood-stage (ABS) whole-cell activity as well as the potential implications for the development of inhibitors of this epigenetic modulator for the treatment of malaria. Results and Discussion We first sought PfGCN5 inhibitors by screening the TCOLF diversity set of compounds using a FRET-based assay that measures the binding between the recombinantly expressed GCN5 bromodomain (2 nM) and an acetylated histone peptide (histone 4 a.a 1–20, K12ac). Compounds that inhibit the binding between protein and peptide should prevent or reduce the FRET signal detection. The affinity between the acetylated peptide and the GCN5 bromodomain was determined using the FRET system (KD = 225 nM). L-45 was used as a tool compound to validate the assay, with a pIC50 of 7 on average. The assay DMSO tolerance was established as being 0.3%, which is not surprising, since DMSO is an acetyl mimetic known for binding to bromodomains. A mock screen was also run as a validation step before the screening of compounds, with plates showing a typical Z′ of 0.9 and an S/B of 30. This compound set (TCOLF diversity set) was initially designed and computationally refined from the GSK collection. The GSK 4 M compound library was virtually filtered using different physicochemical property filters (MW < 500 and cPFI < 9), removing compounds that exhibit assay interference, undesirable mechanisms of action (nuisance compounds), promiscuity (high inhibitory frequency index, IFI), or were restricted for other specific reasons. The resulting compounds were clustered with a path-based fingerprint using Tanimoto similarity in several steps between 0.75 and 0.6. Finally, 200 K compounds were found to represent clusters of more than 2 compounds. Among them, a diversity set of 42K compounds was selected by random selection to build a manageable diverse compound library. Given the availability of structural information for PfGCN5, an additional set of 6.2K compounds was built ad hoc using the high-throughput virtual screening tool (HTVS) and PfGCN5 X-ray structure (PDB 5TPX) in complex with the known PfGCN5 inhibitor L-45. The TCOLF diversity set and PfGCN5 ad hoc set were tested in duplicate at a single concentration (2.5 μM of compound). Compounds showing inhibition >25% in at least one copy were progressed for dose–response evaluation. This resulted in 372 compounds tested in dose–response delivering 6 early hits with an initial pIC50 close to or higher than 5 against PfGCN5. Figure A depicts the workflow used in this hit identification campaign, and Figure B shows the percentage of inhibition obtained for the initially identified hits. (A) Hit identification workflow; (B) Single-shot HTS for the diversity and Ad hoc set at 2.5 μM using FRET-based assay. The green circles represent hit exhibiting >25% inhibition. Further evaluation was carried out to select hits for progression. Initial physicochemical properties (ChromLogD, CAD solubility, and PFI), host cellular toxicity (HepG2), selectivity compared to human PCAF, and antimalarial activity against asexual blood-stage (ABS) parasites were evaluated (Table ). The 6 initial hits were resynthesized and retested delivering similar pIC50 to the HTS results, except compound 1, whose activity was reduced by more than 1 log. None of the evaluated compounds showed cellular toxicity or ABS antimalarial activity against the P. falciparum 3D7 strain, while the ABS assay control Mefloquine displayed a pIC50 of 7.7 ± 0.2, which, at this stage, could be due to low activity against the target. All compounds were evaluated using an orthogonal SPR assay, and selectivity was determined against human PCAF (p300/CBP-associated factor) (Table ). 1Hit Structures and Initial Activity Profile Hit Structures and Initial Activity Profile Resynthesized compounds 1 and 2 displayed similar potencies in the FRET assay, although only compound 2 showed activity in the SPR. Compounds 2 and 5 showed low affinity for HsPCAF (pK d < 4.5), lacked cytotoxicity in HepG2 cells, and possessed favorable physicochemical profiles. Compound 3, with PfGCN5 pIC50 of 6.3 (IC50 0.5 μM), was also explored but none of the examined analogues demonstrated better activity (data not shown). Among the rest of the hits, compound 6 exhibited good initial potency by SPR (PfGCN5 pK d 5.7) but, as expected, it has a higher binding affinity with the human enzyme (HsPCAF pK d 6.5) since it was previously developed at GSK as inhibitor for human PCAF. Due to its high potency and at least 10-fold selectivity over HsPCAF, we initially focused our efforts on compound 2, aiming to increase potency against PfGCN5, improve solubility, and decrease chromLogD while maintaining a low cellular toxicity. In addition, a similar fragment compound, SKT1174, has been previously described as a low-affinity BPTF (Bromodomain PHD Finger Transcription Factor) inhibitor (SPR, K d 280 ± 70 μM) and has been cocrystallized with the protein. This small molecule and compound 2 share a cyclopropylcarbonyl-substituted tetrahydroquinoline moiety, a motif commonly found in other bromodomain inhibitors. BPTF and PfGCN5 are predicted to be structurally related (Figure A) and they present a highly homologous binding pocket (59% sequence identity among residues within 6 Å from the ligand). Furthermore, both proteins have been recently reported to be involved in the acetylation of the nonconserved histone variant H2A.Z. 3D and 2D representation of (A) Superposition of PfGCN5 and BPTF with cocrystallized fragment SKT1174. (B) Molecular docking and predicted binding mode for compound 2 with PfGCN5. (C) PfGCN5 cocrystal structure with L-45. Initial molecular modeling studies point to a binding mode in which the cyclopropylcarbonyl tetrahydroquinoline binds to the PfGCN5 pocket acting as an acetyl lysine mimic, a feature that is typically observed in other bromodomain inhibitors. Compound 2 shares the same interactions with ASN1436 and TYR1393 through a water bridge presented in the fragment SKT1174 cocrystal structure (Figure B). Moreover, L-Moses (or L-45) establishes similar interactions with PfGCN5 (Figure C). Therefore, given this predicted possible binding mode, this part of the molecule was initially left unchanged. Instead, we centered our efforts on modifying the thiazole substitution aiming to understand the role of this substituent and improve potency. Aminothiazole substitution was initially evaluated (Table ). 2SAR1: Aminothiophene Substitution SAR1: Aminothiophene Substitution Different amides, secondary and tertiary amines, and sulfonamides were tested. Initial methylation of the amide (11a) led to a clear loss of activity (PfGCN5 pIC50 < 4.6). Introduction of branching (11b) aiming to reduce clearance led to weak antiplasmodial activity (PfGCN5 pIC50, pIC50 4.6). Encouragingly, the use of cyclic amines such as morpholine (11c) showed a slight increase in potency against GCN5 (pIC50 = 6.4) but no further increase in antimalarial activity. Comparing derivatives 11b and 11c with 12b and 12c, it was clear that thiazole substitution in position C6 of the tetrahydroquinoline exhibited equal or better activity than its corresponding C7-substituted derivatives. Hence, we focused our attention on the preparation of C6-substituted aminothiazole derivatives. The use of aromatic unsubstituted (11d) and substituted amines (11e and 11g) and amides (11f) caused a large drop-in activity. Primary amine 11h, aliphatic amines, and amides retained or slightly impaired activity (11i-11m); in addition, these derivatives showed lower solubility and higher chromLogD and cytotoxicity. Aliphatic sulfonamide derivatives 11n and 11o had a positive impact on physicochemical properties improving cytotoxicity, chromLogD, and solubility. Besides, compound 11n delivered similar potency compared with the corresponding amide 11m (pIC50 6.3 and 6.2, respectively), keeping a low cytotoxicity (pIC50 4.1), chromLogD (3.2), and significantly improving solubility (≥178 μg/mL). Pyridine (11s) and methylpyridine derivative (11t) showed a significant loss of activity (pIC50 < 4.6 and 4.7, respectively) while unexpectedly, contrary to the behavior observed for the initial hit, compound 11r recovered activity when the thiazole amide is methylated (pIC50 5.8) and a positive effect is also observed by SPR. Introduction of a pyrazine (11v) rings slightly decreased potency against the target while substitution of the ring (11u) dropped more than 1 log in pIC50 (5.7 and 4.6, respectively). Other smaller heterocycles such as furan 11w showed similar potency than the hit while methylisoxazole 11x dropped 1 log. Interestingly, the introduction of covalent binders such as acrylamide (11p) and chloroacetamide (11q) showed a positive increase on the activity for both biochemical (pIC50 7.1 and 6.9, respectively) and biophysical measurements (pK d 5.5 and 6, respectively). Both derivatives also showed a significant improvement in ABS activity with pIC50 values of 5.2 and 5.7, respectively, but in both cases, the compounds exhibited significant cytotoxicity in HepG2 with pIC50 values of >5. These results point to a covalent approach as a possible strategy for improving target inhibition. Next, we replaced the thiazole ring with different aromatic, aliphatic, and heteroaromatic five- and six-membered rings (Table ). 3SAR2: Thiophene Scaffold Hopping SAR2: Thiophene Scaffold Hopping Replacement of the thiazole for a 6-membered ring (21a-21f) maintained potency against PfGCN5. The phenyl ring derivative 21a showed a pIC50 of 6.2 in the biochemical assay and low activity in the ABS assay against P. falciparum 3D7 with a pIC50 of 4.5 (IC50 32 μM). Substituted aminopyridines with the nitrogen atom and amide in different positions retained similar activity against both protein and parasite (21b-21d). Compound 21c, although still low, showed the most potent antimalarial activity with a pIC50 of 4.6 (IC50 25 μM) and improved lipophilicity (3.5) and CAD solubility (≥123 μg/mL) together with no cellular toxicity. Also, worth noting, the introduction of a methyl group in position 5 of the pyridine to break planarity was not well tolerated resulting in a 1 log reduction in potency (21f pIC50 5.2 vs 21d pIC50 6.4). This detrimental effect upon methylation was also observed for thiazole (21j) with lower potency (pIC50 4.9), lower solubility (3 μg/mL), and increased lipophilicity (5.2). Likewise, the introduction of a thiadiazole ring (21g) resulted in a loss of potency. In contrast, the thiophene analogue (21i) improved activity against the protein and displayed a weak antiplasmodial activity (PfGCN5 pIC50 6.5 and ABS 3D7 pIC50 4.5) but significant increase in cellular toxicity (HepG2 pIC50 5.0). Introduction of N-methylpyrazole (21k), imidazole (13) or pyrazole (21h) led to an increase in potency with pIC50 of 6.1, 6.3, and 6.6, respectively, but no ABS activity. Finally, the use of aliphatic heterocycles such as pyrrolidine (34) led to a decrease in potency compared with the initial hit. From the different rings evaluated, compounds 21h and 21i showed the best results with 21h, which incorporates a pyrazole ring, being the most potent analogue with PfGCN5 pIC50 of 6.6 (275 nM), lower chromLogD (2.9), good solubility (≥117 μg/mL), and low cytotoxicity (pCI50 HepG2 4.3). Subsequently, after evaluating the effect of the position and substitution of the aminothiazole, we addressed the effect of the tetrahydroquinoline structure on the activity (Table ). Again, a clear influence of the aminothiazole position on the activity was observed with different tetrahydroquinoline-modified scaffolds. Methylation of the tetrahydroquinoline (15b) retained some activity (pIC50 5.4), while a similar drop in pIC50 was observed when O (26b) or S (27b) atoms were introduced in the aliphatic ring (pIC50 5.5 and 5.8, respectively). Finally, ring contraction (18) or expansion (28a) and changes on the cyclopropyl position (17) negatively affect potency, rendering the compounds inactive. 4SAR3: Tetrahydroquinoline Modification SAR3: Tetrahydroquinoline Modification Next, the effect of the cyclopropyl substituent was evaluated (Table ). In this part of the molecule, replacing the amide group with a sulfonamide (14) negatively impacted activity, rendering the compound inactive. Similarly, replacing cyclopropyl with a methyl was not tolerated (16a). 5SAR4: Cyclopropyl Amide Modifications SAR4: Cyclopropyl Amide Modifications Due to the presence of reactive amino acids (CYS1430 and CYS3003) in the PfGCN5 active site, we decided to explore a covalent approach to facilitate target engagement. Introduction of a chloroacetamide (22) or acrylamide (23) warhead showed moderate potency against P. falciparum. Thus, chloroacetamide derivative 22 (pIC50 5.0 in 3D7) was the most potent inhibitor of parasite growth. However, mass spectrometry analysis indicated no binding to the protein for chloroacetylamide and acrylamide derivatives. The introduction of an epoxide (25) was not tolerated. These analogues with covalent warheads demonstrated differentiated cytotoxicities in HepG2. Chloroacetamide derivative (22) displayed significant toxicity (pIC50 5.4), while acrylamide and epoxide derivatives (23 and 25) were less toxic (pIC50 4.5 and 4.2, respectively). A summary of the SAR for compound 2 is displayed in Figure A. The SAR exploration carried out for compound 2 was extensive, including newly designed compounds reported here and more than 100 analogues retaining the substituted tetrahydroquinoline scaffold that were available at GSK and were tested against PfGCN5. Figure B collects the pCI50 of all the evaluated analogues measured by HTRF against their experimental chromLogD, and Figure C summarizes the improved profile for the hit and best analogue 21h. Although a clear improvement in the physicochemical profile and potency against the target was obtained, there was a disconnection between GCN5 binding and the phenotypic activity against Plasmodium in the ABS assay. Therefore, the optimization of this compound series was stopped, and other chemical series were selected for further investigation. (A) SAR summary for compound 2 as PfGCN5 inhibitors. (B) PfGCN5 pIC50 vs ChromLogD representation of all evaluated compounds. (C) Hit and best analogue 21h activity and initial physicochemical profile. As a final attempt to increase the potency of the initial hit 2, the synthesis of a bivalent compound was pursued (Figure ). The synthesis of symmetrical and pseudo-symmetrical bivalent inhibitors has been successfully applied in the design of BET bromodomain inhibitors, delivering bivalent compounds with a significant increase of potency compared with the initial monovalent inhibitor. From 11h, the bivalent derivative 11y was initially synthesized and evaluated to explore this alternative approach. In our case, although we were pleased to observe that our bivalent inhibitor shows a significant increase in ABS activity compared with the initial hit 2 (pIC50 of 5.6 and <4.3, respectively), this increase in phenotypic potency was not driven by an increase in binding affinity for PfGCN5 compared with the hit. Hit and bivalent analogue 11y activity and initial physicochemical profile. Compound 5, identified from the HTS, exhibited lower potency (pIC50 of 5.3) compared to hit 2 but higher solubility (≥182 μg/mL) and lower chromLogD (2.71). Compound 5 contained a substituted N-methylpicolinamide group which represents a classic acetyl lysine mimic commonly found in other bromodomain inhibitors. As shown for the previously explored hit 2 and L-Moses (Figure A and B), compound 5 shares the same interaction among the TYR1442, CYS1432, and TYR1393 (water bridge) with the N-methylpicolinamide moiety (Figure ). So, this part of the molecule was initially left untouched. Molecular docking and predicted binding mode for compound 6 with PfGCN5. In the first approach, we aimed to reduce the flexibility of the substituted piperidine. However, reducing the length and flexibility of the aliphatic linker (41a) led to a slight decrease in activity (from 5.3 to 5.0) (Table ). Replacing the aliphatic piperidine with a more rigid phenyl ring improved the inhibitory activity delivering 41b with a pIC50 of 6.5 against PfGCN5. Incorporating aromatic heterocycles including well-known antimalarial scaffolds such as quinoline with extended linkers had a positive impact on compound activity, although this increase in potency came at the cost of increased lipophilicity and PFI. Compound 41c with a phenyl ring substitution of the N-methylpicolinamide and a methyl quinoline separated by a spacer retained similar activity to 41b (6.5 and 6.3, respectively). Interestingly, in this case, a shorter linker and restricting flexibility (41d) led to a significant improvement in activity delivering the most potent derivative against PfGCN5 with a pIC50 of 7.0. Biophysical evaluation delivered similar potency for both analogues (pK d 5.6 and 5.5). Methylation of the piperazine heterocycle (41e) recovered significant inhibitory activity with a pIC50 of 6.2 while the replacement of the aromatic ring for other heterocycles such as pyrazole (41f) led to a loss of activity (pIC50 of 5.5). Finally, replacement of the piperazine in 41c moiety with a piperidine (41h) improved potency, achieving a pIC50 of 6.7, while also enhancing both lipophilicity (4.1 vs 5.7) and solubility (78 vs 24 μg/mL). This resulted in a significant improvement in binding, increasing the pK d value from 5.6 to 6.0. Encouragingly, derivatives 41e and 41h with 2-methylpiperazine and piperidine moieties, respectively, showed activity against the parasite (pIC50 5.1 and 5.9, respectively). 6Activity of Hit 5 and Analogues Activity of Hit 5 and Analogues However, it is important to highlight that while the presence of the N-methylpicolinamide moiety seems to be crucial for the inhibitory activity against the target, it is not essential for the activity against the parasite. For instance, compounds 41g with a primary amide and 41k with an ethyl ester group are inactive against the target (pIC50 < 4.6) but retained significant activity against the parasite (pIC50 5.5 and 6.3, respectively). Similar behavior is observed for compounds 41i and 41j, where the replacement of the aromatic ring in 41h with a thiazole or the pyridine moiety with a dihydroimidazo­[1,5-a]­quinoline retains ABS activity (pIC50 of 5.7 and 6.4, respectively) but with a significant drop in potency against the target protein (pIC50 of 5.4 and 5.0). These results suggest that PfGCN5 inhibition may not be the primary driver of ABS antimalarial activity in this series. While inhibition of β-hematin metabolism is a well-known property of quinoline-containing compounds, the mechanism underlying this weak whole-cell activitypotentially independent of PfGCN5remains unclear and would require investigation beyond the scope of this manuscript. It is possible that a similar behavior could account for the ABS activity for compounds 41e, 41f, 41g, 41h, 41i, 41j, and 41k. Figure A summarizes the SAR observed for compound 5. Besides the compounds presented in Table , more than 100 analogues computationally selected from the GSK collection were tested during several hit expansion iterations. Compounds were selected bearing the N-methylpicolinamide moiety and with substitutions at different positions of the pyridine ring. However, many substitutions on the pyridine ring were not tolerated. Figure B represents all tested compounds in PfGCN5 vs lipophilicity, and Figure C summarizes the results obtained for the hit and best analogue 41h. (A) SAR summary for compound 2 as GCN5 inhibitors (B) PfGCN5 pIC50 vs ChromLogD for all evaluated compounds. (C) Hit and best analogue (41d) activity and physicochemical profile. 7Permeability Data in MDCK-MDR1 Cells in the Presence of a P-Glycoprotein Inhibitor Permeability Data in MDCK-MDR1 Cells in the Presence of a P-Glycoprotein Inhibitor To rationalize the disconnect between the biochemical potency against PfGCN5 and the potency against the parasite, we measured other physicochemical properties that could influence the target engagement in the parasite. We measured the permeability of the compounds in MDR1-transfected MDCK2 cells to assess their ability to cross cellular membranes and evaluate P-glycoprotein efflux transport. As shown in Table , compounds 41e and 41h, despite exhibiting significantly lower solubility and permeability compared to the initial hit (6), displayed some antimalarial activity against P. falciparum with a pIC50 > 5. For hit 2, replacing the amide with a sulfonamide (11n) increases the solubility (30 to ≥178 μg/mL, respectively) but results in lower permeability (157 and 60.5 nm/min). Scaffold hopping to an aminopyrazole (21h) again led to an improvement in solubility (≥117 μg/mL) retaining good permeability (160 nm/min). Also, except for the initial hit 2, these two analogues (11n and 21h) show clear changes in the efflux rate when assessed in MDCK2-MDR1 assays with Elacridar (P-glycoprotein inhibitor) (5.1 and 6.8) demonstrating to be substrates of the transporter. Thiophene derivative 21i, although it is not a P-glycoprotein substrate, shows a drop in permeability (70.5 nm/min) and low solubility (23 μg/mL). Finally, compounds 21b and 21c, which have similar potencies in both the target and parasite, exhibit a clear influence of the propylamide position on their behavior as P-glycoprotein substrates, solubility, permeability, and toxicity which improves when the amide is in position C4 of the pyridine ring (21c). For this family of compounds, the combination of low solubility and low permeability might account for the low activity observed in ABS assays. Chemistry Compound 2 preparation was initially approached through a classic Hantzsch thiazole synthesis from the corresponding α-chloroketone tetrahydroquinoline derivative 9a with substituted thiourea 10a (see Scheme ). Friedel-Craft acylation of tetrahydroquinoline derivative 8 delivered compound 9a as an inseparable mixture of the acylated derivatives in positions C6 and C7 (as major and minor derivatives, respectively). Subsequent formation of the thiazole ring and separation of both products allowed the preparation of compound 2. Synthesis of Hit Molecule 2 and Corresponding Analogues through Hantzsch Thiazole Synthesis; a) Cyclopropyl Carbonyl Chloride, Et3N, DCM; b) AlCl3, 2-Chloroacetyl Chloride, DCE; c) EtOH, 80 °C; d) (i) 1-Methylthiourea, EtOH, 80 °C and (ii) Propionyl Chloride, DCM, Pyridine, 31% (over 2 Steps); e) Et3N, DCM; f) Pyridine, DCM; g) TBTU, DMF, Et3N, r.t.; h) N-carbamimidoylacetamide, MeCN, MW, 100 °C Derivatives 11a-h and 12b-d, h were obtained from the corresponding substituted thioureas. For compounds 11e-g, complete separation of the substituted thiazole in position C7 was not possible, and only the desired derivative substituted in position C6 was obtained pure. Derivatives 11j-11q were obtained through direct acylation of the aminothiazole 11h with subsequent carboxylic acids, acyl or sulfonyl chlorides using different reaction conditions. Imidazole derivative 13 was obtained by following the same approach using acetylated guanidine to access the desired heterocycle. Scaffold-hopping derivatives were synthesized according to the route depicted in Scheme . Compounds 21a-k were obtained in moderate to good yields (49–79%) through Suzuki-Miyaura cross-coupling between propylated aryl/heteroaryl iodide or bromide derivatives and boronic pinacolester tetrahydroquinoline 20a. Preparations of the covalent warhead derivatives 20b–e were obtained following the same synthetic approach. Scaffold Hopping Analogues Synthesis; a) Et3N, Cyclopropanecarbonyl Chloride, DCM; b) Pd­(dppf)­Cl2·DCM, K2CO3, Dioxane/H2O (2:1), 80 °C Modification of the tetrahydroquinoline moiety was achieved by following two different approaches Derivatives 17 and 18 (Scheme ) were synthesized using the same synthetic strategy to that of the hit compound. Friedel-Craft acylation and Hantzsch thiazole synthesis with N-carbamimidoylacetamide delivered thiazole derivatives in position C6. Synthesis of Analogues 17 and 18 through Hantzsch Thiazole Synthesis; a) Cyclopropanecarbonyl Chloride, Et3N, DCM; b) AlCl3, 2-Chloroacetyl Chloride, DCE; c) N-carbamothioylpropionamide, EtOH, 80 °C (A, B) Tetrahydroquinoline Modified Analogue Synthesis; a) Cyclopropanecarbonyl Chloride, Et3N, DCE; b) 2-Chloroacetyl Chloride, AlCl3, DCE; c) N-carbamothioylpropionamide, EtOH, 80 °C; d) B2Pin2, Pd­(dppf)­Cl2·DCM, AcONa, Dioxane, 80 °C; e) N-(4-Bromothiazol-2-yl)­propionamide, Pd­(dppf)­Cl2·DCM, K2CO3 Dioxane/H2O (2:1), 80 °C; f) Pd2(dba)3, tert-Butyl Pyrrolidin-3-ylcarbamate, DavePhos, tBuONa, Dioxane, 90 °C; g) HCl·Dioxane, MeOH; h) Propionyl Chloride, Et3N, DCM In the case of the benzoxazine 26 and benzothiazine 27 derivatives, initial Friedel-Crafts acylation exclusively installed the α-chloroketone substituent in position C7 (Scheme A), and a different approach was required to access the desired C6-substituted tetrahydroquinoline analogues (Scheme B). Synthesis was carried out starting from the corresponding 6-bromo-benzoxamine 29a, 6-bromo-benzothiazine 29b, and 7-bromo-benzoazepine derivative 29c. Initial Miyaura borylation delivered the corresponding boronic ester derivatives 31a-c which were reacted with N-(4-bromothiazol-2-yl)­propionamide to yield the corresponding thiazole-substituted tetrahydroquinoline analogues 26a, 27a, and 28a. The corresponding aliphatic analogue 34 was obtained through direct Buchwald coupling of the 6-bromotetrahydroquinoline derivative 30d with tert-butyl pyrrolidin-3-ylcarbamate to deliver compound 34 in good yield, after Boc-deprotection and acylation with propionyl chloride. Finally, bivalent inhibitor 11y (Scheme ) was obtained in a low yield (8%) by direct amide coupling between 2,2′-(ethane-1,2-diylbis­(oxy))­diacetic acid used a linker and thiazole amine derivative 11h using classic coupling agents (HATU/DIPEA) in DMF as reaction conditions. Synthesis of Bivalent Inhibitor 11y; a) HATU/DIPEA, DMF, 48 h, r.t. (8%) The synthesis of series 6 hit and analogues is depicted in Scheme . Compounds 5 and 41a were obtained through Buchwald-Hartwig amination between the corresponding substituted piperidines 39a and 39b and 6-iodo-N-methylpicolinamide 40. Derivative 41b was synthesized following a similar approach by means of Suzuki-Miyaura cross-coupling with a substituted phenylboronic ester derivative 42. Synthesis of 5 and Analogues; a) Pd­(OAc)2, BINAP, Dioxane, 100 °C; b) Pd­(dppf)­Cl2·DCM, K2CO3, Dioxane/H2O, 80 °C, 95%; c) H2, Pd/C, EtOH, 40 psi, 14%; d) HCl, Dioxane/MeOH, 95%; e) NaBH­(OAc)3, DCE, AcOH; f) B2Pin2, Pd­(dppf)­Cl2·DCM, K2CO3, Dioxane/H2O, 80 °C Final compounds 41c, 41d, and 41h were obtained following a similar approach. Piperazine 46a or piperidine 46c derivatives were elongated with phenyl 48- and benzyl 47-substituted aldehydes through reductive amination to deliver bromide derivatives 48a, 48c, or boronic acid derivative 49b. Boronic ester group was installed in compounds 47a and 47c by Miyaura borylation. Final Suzuki-Miyaura cross-coupling with 6-iodo-N-methylpicolinamide 40 delivered desired compounds in moderated good yields. Conclusions In summary, the screening of a subset of 48,200 compounds from the GSK collection led to the identification of novel, tractable inhibitors of PfGCN5 bromodomain. Despite the improvements in their properties after a SAR survey, the lead compounds did not show the expected parasite growth inhibition. Based on prior observations across comparable programs, we typically see an approximately 1.0–1.5 log shift between biochemical pIC50 and whole-cell pIC50, so compounds with HTRF pIC50 ≥ 6 would be expected to show measurable whole-cell activity (pIC50 > 4.5); however, most compounds do not meet this threshold, indicating a disconnect between biochemical potency and cellular efficacy. Moreover, Jingyi Tang et al. recently reported that PfGCN5ΔBRD parasites could not survive beyond 20 generations, but even though PfGCN5:HA protein was undetectable by 72 h after rapamycin treatment, a significant decrease in parasite growth was not observed until 88 h. Furthermore, tool compounds previously demonstrated to possess strong antimalarial activity have been found to interact with PfGCN5; however, this antimalarial effect may not be exclusively attributed to PfGCN5 inhibition. The mere presence of compound binding and apparent gene essentiality does not establish causality. Therefore, assertions regarding bromodomain inhibition of PfGCN5 as the mechanism for parasite growth suppression should be made with caution, until further validation is obtained. To address this, we plan to perform resistance selection with the most potent compounds, followed by whole-genome sequencing (WGS) to identify resistance-associated changes and assess on-target engagement. PfGCN5 was prioritized based on reported genetic essentiality and the availability of tool compounds. In hindsight, the target rationale could have been further supported before fully committing medicinal chemistry resources. Complementary validationsuch as conditional knockdown experiments to confirm essentiality, quantify the extent of knockdown required to induce parasite death, and determine time-to-killwould have clarified the therapeutic potential and liabilities. This data package suggests that targeting the PfGCN5 bromodomain to develop antimalarial compounds might not be as effective as expected and raises the question of whether solely targeting the bromodomain region on PfGCN5 effectively translates into parasite death. Nonetheless, BDR inhibitors might be slow-acting compounds with potency increasing when evaluated over longer time points. This delayed effect could potentially align with the development of chemoprophylactic drugs that are intended to prevent infection over extended durations. A different strategy to knock down the protein, such as targeted protein degradation, might also be considered in order to increase antiplasmodial potency. Importantly, the inability of PfGCN5:ΔBRD parasites to form infective stage V gametocytes, together with inhibition of sporozoite development, indicates that PfGCN5 BRD inhibitors could also serve as transmission-blocking agents. Alternatively, PfGCN5 upregulation during stress conditions has been associated with the generation of artemisinin resistance in P. falciparum, and a decrease of resistance levels has been reported in the presence of weak PfGCN5 inhibitors. Although current data indicate that the development of clinical candidates for this protein might be challenging, inhibition of this target could still be exploited as a resensitizing strategy for artemisinin-resistant strain lines. Experimental Section General Methods Chemicals and solvents were purchased from Sigma-Aldrich, Combi-Blocks, and Enamine and were used as received. Oxygen- and moisture-sensitive reactions were carried out under an inert atmosphere of nitrogen. Dry solvents were purchased in Sure Seal bottles (DMF and DCM stored over molecular sieves). Flash column chromatography was performed using prepacked silica gel iLOK and SiliCycle cartridges of different sizes using a Biotage Isolera CombiFlash. 1H NMR and 13C NMR spectra were recorded on a Bruker Avance NEO 400 spectrometer (1H at 400.1 MHz, 13C at 101.8 MHz). Chemical shifts (δ) are expressed in ppm registered using the residual solvent as the internal reference (DMSO–D6, CD3OD, or CDCl3) in all cases. Signal splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), quintuplet (quin), sextuplet (sxt), multiplet (m), broad (br s), or a combination thereof. Coupling constants (J) are quoted to the nearest 0.1 Hz. Reactions were followed using precoated TLC aluminum plates (Kieselgel 60 F254, 0.2 mm, 40 × 80 mm, ALUGRAM SIL) or low-resolution mass spectrometry recorded on an Agilent Technologies 1290 Infinity Series HPLC connected to an Agilent Technologies 6120 quadrupole LCMS, connected to an Agilent diode array detector, where the column used was a Waters XBridge column (4.6 mm × 50 mm, 3.5 μm particle size) with a gradient of 5–90% using 0.05 MM NH4HCO3 in water (solvent A) and acetonitrile (solvent B) as a mobile phase. Preparative Agilent HPLC chromatographic separations were performed using a Waters X-Bridge C18 column (1 injection, 50 mm × 150 mm, 5 μm particle size, flow 100 mL/min, G7161B pumps, prep autosampler G7157A), connected to a G7115A UV/vis detector alongside a 1260 DAD WR, using 0.05 MM NH4HCO3 in water (solvent A) and acetonitrile (solvent B) as a mobile phase. The fractions containing product were collected, solvents evaporated in vacuo, subjected to Genevaćs EZ-2 Elite centrifugal evaporator, and then dried in the oven under 40 °C overnight to give the appropriate purified sample. All final compounds showed chemical purity of ≥95%, except compound 12c (purity = 93%), as determined from the UV chromatogram (210–500 nm) obtained by UPLC analysis, conducted on an Acquity UPLC BEH (MS: Waters SQD; injection volume 1 μL, 1.7 μM, C18 3 × 50 mm column at 50 °C) with a gradient of 5–100% acetonitrile/water +0.1% formic acid, a flow rate of 0.8 mL/min, and a time of 2 min. Microwave-assisted chemistry was performed using a Biotage Initiator+. The synthesis of the intermediates and characterization data for the final compounds are included in the Supporting Information. Biological Assays ABS Assay Protocol Plasmodium falciparum asexual blood-stage assay. Assays against P. falciparum were conducted as previously described. Human erythrocytes were obtained with ethical approval from national blood transfusion services. Cultures of the widely used malaria reference strain chloroquine-sensitive P. falciparum 3D7 were maintained in a 5% suspension of human red blood cells cultured in RPMI 1640 medium supplemented with 0.5% Albumax II (available from Gibco Life Technologies, San Diego, CA, cat. no. 11021–037), 12 mM sodium bicarbonate, 0.2 mM hypoxanthine (pH 7.3), and 20 mg/L gentamicin at 37 °C, in a humidified atmosphere of 1% O2, 3% CO2 with a gas balance of nitrogen. Growth inhibition of P. falciparum cultures was quantified in a 10-point dose–response curve with a 1-in-3 dilution series from a top assay concentration of 50 μM. This 384-well plate-based fluorescence assay utilizes the binding of SYBR Green I (Thermo Fisher Scientific/Invitrogen cat. no. S7585) to double-stranded DNA, which greatly increases the fluorescent signal at 528 nm after excitation at 485 nm. Mefloquine was used as the inhibition control. Assay quality was monitored using Z′: Z´=1−3×[SDRCtrl1+SDRCtrl2RCtrl1−RCtrl2] Z′ values between 0.6 and 0.8 were obtained for all plates (cutoff Z′ > 0.4). Dose–response curves (10 points, dilution 1/3) were determined from a minimum of 3 independent experiments. Compound bioactivity was expressed as EC50, the effective concentration of compound causing 50% parasite death. Data were analyzed using ActivityBase XE and SIGNALS VitroVivo (SVV) Analysis Software. Each point of the curve was calculated with the percentage of inhibition, based on the response of each compound (x) and normalized with the average of controls. %Inhibition(x)=100−100×Avx−AvCtrl1AvCtrl1−AvCtrl2 Protein Expression and Purification PfGCN5 Bromodomain His 6 tag. The gene encoding P. falciparum bromodomain (1356–1460) was synthesized with an N-terminal, TEV-cleavable His6 tag (Twist Bioscience) and cloned into a pET29a vector using NdeI/XhoI restriction sites added at the 5′ and 3′ ends of the gene. The plasmid was transformed into E. coli BL21­(DE3). A single colony was used to inoculate a 10 mL starter culture and grown at 37 °C overnight. The starter culture was used to inoculate 1 L TB media and grown at 37 °C until an OD600 of 0.6–0.8 was reached. The temperature was reduced to 20 °C before the addition of IPTG to a final concentration of 0.15 mM and incubation for 18 h. Cells were resuspended in lysis buffer (20 mM HEPES, 500 mM NaCl, 10 mM imidazole, 1 mM TCEP, 5% w/v glycerol, pH 7.5, DNase I, protease inhibitor cocktail) and lysed with a continuous flow cell disruptor (Constant Systems) at 30 kpsi. Protein was purified by Ni-NTA affinity chromatography (a linear gradient of 10–500 mM imidazole) followed by size exclusion chromatography. Protein was concentrated to 10 mg/mL in 10 mM HEPES, 100 mM NaCl, 0.5 mM TCEP, pH 7.5, and stored at −80 °C. His 6 -GST tag. The P. falciparum bromodomain (1356–1460) was cloned into a Ligation-Independent Cloning (LIC)-modified pNIC28a vector for expression with an N-terminal, TEV-cleavable His6-GST tag. A single colony was used to inoculate a 5 mL starter culture and was grown at 37 °C overnight. The starter culture was used to inoculate 0.5 L TB media and was grown at 37 °C until an OD600 of 0.6–0.8 was reached. The temperature was reduced to 18 °C before the addition of IPTG to a final concentration of 0.5 mM and incubation for 18 h. Cells were resuspended in lysis buffer (25 mM HEPES, 500 mM NaCl, 20 mM imidazole, 0.5 mM TCEP, 5% w/v glycerol, pH 7.5, DNase I, protease inhibitor cocktail) and lysed with a continuous flow cell disruptor (Constant Systems) at 30 kpsi. Protein was purified by Ni-NTA affinity chromatography (a linear gradient of 20–500 mM imidazole) followed by size exclusion chromatography. Protein was concentrated to 3 mg/mL in 25 mM HEPES, 150 mM NaCl, 0.5 mM TCEP, 5% w/v glycerol, pH 7.5, and stored at −80 °C. Protein Expression and Purification of Human PCAF Bromodomain Synthetic DNA encoding full-length human PCAF was ordered from GenScript and cloned into a Ligation-Independent Cloning (LIC)-modified pNIC28a vector for expression of PCAF bromodomain (715–832) with an N-terminal, TEV-cleavable His6-linker-His6 tag. A single colony was used to inoculate a 10 mL starter culture and grown at 37 °C overnight. The starter culture was used to inoculate 1 L TB autoinduction media and grown at 37 °C for 4 h. The temperature was reduced to 20 °C and incubated for 18 h. Cells were resuspended in lysis buffer (50 mM Bis-Tris, 125 mM NaCl, 20 mM imidazole, pH 6.5, DNase I, protease inhibitor cocktail) and lysed with a continuous flow cell disruptor (Constant Systems) at 30 kpsi. Protein was purified by Ni-NTA affinity chromatography (a linear gradient of 20–500 mM imidazole) followed by size exclusion chromatography. Protein was concentrated to 1.5 mg/mL in 50 mM Bis-Tris, 125 mM NaCl, pH 6.5, and stored at −80 °C. HTRF Assay Purified PfGCN5BRD conjugated with GST and a histone 4 acetylated and biotinylated peptide (Alta Bioscience, cat. no. HS26) were diluted in binding buffer (part of Cisbio EPIgeneous Binding Domain Kit B, cat. no. 62BDBPEH). GST-Eu3+ cryptate antibody and streptavidin-XL665 conjugate were diluted in detection buffer (all components of Cisbio EPIgeneous Binding Domain Kit B, cat. no. 62BDBPEH). Four μL of PfGCN5, 4 μL of peptide, 5 μL of antibody, 5 μL of SA-XL665 solution, and 2 μL of binding buffer were added to wells of white 384-well low-volume plates (Greiner, cat, no. 784904) yielding final concentrations of 2 nM for PfGCN5, 200 nM for histone peptide, 0.125X for Eu antibody, and 25 nM for SA-XL665. Plates were prestamped with compounds using an acoustic dispenser. The final DMSO concentration was kept at 0.25%. The system was incubated for 2 h and 30 min at room temperature, and TR-FRET measurements were acquired on a PHERAstar plate reader (BMG): 337 nm excitation, 620 nm (Eu) and 665 nm (XL665) emissions, delay 60 μs, integration 400 μs. The TR-FRET ratio was taken as the 665/620 nm intensity ratio, multiplied by a factor of 104. Three independent experiments were run for dose–response plates (11 points, dilution 1/3) and two independent experiments were run for single-shot experiments. Data were analyzed using ActivityBase XE and SIGNALS VitroVivo (SVV) Analysis Software. Quality control statistical analysis was performed using Z′ as the referenced parameter. RCtrl1 and RCtrl2 were calculated as the average of control 1 (DMSO) and control 2 (L-45). For all the experiments, the Z′ range was 0.7–0.9 and Signal/Background around 30. The percentage of inhibition was calculated based on the response of each compound (x) and normalized with the average of controls. In the single-concentration assays, robust cutoffs at the robust mean+3xSD of control 1 were used to consider compounds as active. For this project, active compounds that exhibited a percentage inhibition of >25% were selected as hits. SPR Assays In a Biacore 8K+ SPR instrument (Cytiva), His6xPfGCN5 or His6xPCAF protein (7 μg/mL) was immobilized onto FC2 of an NTA-derivatized linear polycarboxylate hydrogel, medium charge density, 1500 M chip (Xantec, cat. no. SCBS NiHC1500M) by nickel capture and amine coupling (Amine Coupling Kit , Cytiva cat. no. BR100050). Eight channels were used in parallel, and a typical response of around 4000 RU was obtained for PCAF and that of 2000 RU was obtained for PfGCN5. FC1 was used as the reference surface, dilution buffer composition: 25 mM HEPES, 150 mM NaCl, 0.5 mM TCEP, pH 7.5. A concentration series was prepared for the compounds as a 6-point, 3-fold dilution (top concentration 30 μM, DMSO kept fixed at 0.3%) by the addition of 100 μL of dilution buffer to the wells of a 384-well plate (Greiner, cat. n0. 78128) prestamped with compounds using an Echo acoustic dispenser (Beckman). Blank buffer (25 mM HEPES, 150 mM NaCl, 0.5 mM TCEP, pH 7.5, 0.3% DMSO) solutions were run between each compound for double subtraction (FC 2–1 = first subtraction, compound cycle-blank cycle = second subtraction). Samples were injected at 30 μL/min over the PfGCN5 or PCAF and the reference surfaces with an association phase of 60 s followed by a dissociation phase of 120 s. A 5-point DMSO calibration curve was also included (solvent correction, DMSO 0.1–0.5%). A control compound (GSK4027) was injected as a 6-point, 3-fold dilution concentration series (10 μM top) at the beginning and end of the experiment, in each channel. Data were analyzed using the Biacore Insight Evaluation Software 5.0.18.22102. ChromLogD ChromLogD was measured as previously described: Valko K.; Bevan C.; Reynolds D. Chromatographic hydrophobicity index by fast-gradient RP-HPLC: A high-throughput alternative to logP/logD. Anal. Chem. 69, 1997, 2022–2029 and Robert J. Young, Darren V.S. Green, Christopher N. Luscombe, Alan P. Hill; Getting physical in drug discovery II: The impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discovery Today. 16, 17–18, 2011, 822–830. CAD Solubility Kinetic aqueous solubility was measured using a previously described protocol: M. W. Robinson, Hill, A. P, Readshaw, S. A., Hollerton, J. C., Upton, R. J., Lynn, S. M., Besley, S. C., Boughtflower, B. J. Use of Calculated Physicochemical Properties to Enhance Quantitative Response When Using Charged Aerosol Detection. Anal. Chem. 2017, 89, 1772–177 DOI: 10.1021/acs.analchem.6b04060Anal. HepG2 Cell cytotoxicity assay was performed as previously described: Crouch, S. P. M.; Kozlowski, R.; Slater, K. J.; Fletcher, J. The Use of ATP Bioluminescence as a Measure of Cell Proliferation and Cytotoxicity. J. Immunol. Methods. 1993, 160, 81–88. MDCK2-MDR1 Permeability Assay MDCK2-MDR1 cell monolayers were grown to confluence on PET membranes in 96-well plates. The permeability assay buffer was HBSS (Hank’s Balanced Salt Solution) at a pH of 7.4. The dosing solutions contained 3 μM test compound in the assay buffer, lucifer yellow, and 0 or 2 μM elacridar (P-glycoprotein inhibitor). Cell monolayers were dosed on the apical side (A-to-B) or basolateral side (B-to-A) and incubated at 37 °C with 5% CO2 in a humidified incubator. Samples were collected from the donor and receiver chambers at 90 min. Each determination was performed in duplicate. The codosed lucifer yellow flux was also measured for each monolayer to ensure the integrity of the cell monolayers during the flux period. Samples were extracted by protein precipitation with organic solvents containing an internal standard. The study samples were analyzed by LC-MS/MS, and the permeability and efflux ratio of the compounds were determined from the peak area ratios as detailed below: The apparent permeability (P app), exact permeability (P exact), efflux ratio (ER), and percent recovery were calculated using the following equations: where Papp=Vr×CrA×t×Cdos×107nm/s Pexact,A>B=−(Vd×Vr(Vd+Vr)×A×t)×ln(1−(Vd+Vr)×Cr(Vd×Cd)+(Vr×Cr))×107nm/s ER=PB>APA>B RecoveryA>B(%)=(Vd×Cd)+(Vr×Cr)(Vd×Cdos)×100 V r = volume of the receiver compartment. V d = volume of the donor compartment. C r = PAR in the receiver compartment. C d = PAR in the donor compartment. A = area of the cross-section of the membrane. t = sample time. C dos = average PAR in the dosing solution. An efflux ratio of >2 in the absence of inhibitor that collapses to near 1 in the presence of inhibitor is considered indicative of P-glycoprotein-mediated efflux. Ad Hoc Library Preparation and Virtual Screening Ligands were prepared using Maestro LigPrep at pH= 7.4 ± 0.5, retaining specific chirality and including all stereocenters when the absolute configuration was not known. The PfGCN5 X-ray structure (PDB 5TPX) was prepared using the default option in the Maestro Protein Preparation Wizard. The protein grid was generated without any constraints using the cocrystallized ligand as a reference. A conserved water molecule (HOH 1607) near Tyr1393 was kept in the binding pocket of L-45 for the HTVS docking. A 56K available library was docked at the HTVS level, and results were filtered according to the best pose (with a small RMSE with respect to the L-45 pose) and with a docking score of less than −5.5 kcal/mol, which was 3 kcal/mol lower than the docking score of the reference ligand (−8.3 kcal/mol). In this range, 6.2K compounds were selected for the screening. Docking Protocol Docking of the hits included in Table was performed with the extra precision (XP) mode using Glide. Ligand sampling was set to flexible and included Epik state penalties to docking score. The hydrogen bonds with HOH1607 and Tyr1393 were selected as constraints, where at least one of them must match. Initial Hits Synthesis Preparation of 4-(1-(2-(azepan-1-yl)­acetyl)­pyrrolidin-3-yl)- N -methylpiperidine-1-carboxamide (1). Step 1. Synthesis of tert -butyl 4-(1-(2-(azepan-1-yl)­acetyl)­pyrrolidin-3-yl)­piperidine-1-carboxylate. 2-(Azepan-1-yl)­acetic acid (148 mg, 0.94 mmol) and 1-(bis­(dimethylamino)­methylene)-1H-benzo­[d]­[1,2,3]­triazole-1-ium 3-oxide tetrafluoroborate (328 mg, 1.02 mmol) were dissolved in DMF (5 mL). DIPEA (0.275 mL, 1.57 mmol) was added and the reaction mixture was stirred for 30 min followed by the addition of tert-butyl 4-(pyrrolidin-3-yl)­piperidine-1-carboxylate (200 mg, 0.786 mmol). The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was treated with water (50 mL), extracted with EtOAc (3 × 20 mL), washed with brine (30 mL), and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and the crude was dissolved in 2 mL of MeOH and purified by preparative HPLC. The fractions containing product were collected and the solvents evaporated in vacuo to yield 191.8 mg (62%) of the desired product. LCMS of the isolated product showed the desired product [M + H]+ = 394, 100% UV = 95.2, Rt = 2.80 min (XBridge 0–100 Basic, 5 min). Step 2. 2-(Azepan-1-yl)-1-(3-(piperidin-4-yl)­pyrrolidin-1-yl)­ethan-1-one, Hydrochloride. tert-Butyl 4-(1-(2-(azepan-1-yl)­acetyl)­pyrrolidin-3-yl)­piperidine-1-carboxylate (190 mg, 0.48 mmol) was dissolved in methanol (2.5 mL) at 0 °C. HCl (2.5 mL, 10 mmol) in Dioxane (4M) was slowly added and the reaction mixture was stirred allowing to warm up to room temperature for 2 h. The solvent was removed under reduced pressure to deliver 155 mg (97%) of the desired product as a yellowish sticky oil. The product was used in the next step without further purification. LCMS [M + H]+ 294. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.45–1.73 (m, 8 H), 1.74–1.80 (m, 1 H), 1.82–1.98 (m, 5 H), 2.01–2.17 (m, 2 H), 2.74–2.91 (m, 2 H), 2.93–3.14 (m, 1 H), 3.21 (s, 3 H), 3.22–3.29 (m, 5 H), 3.35–3.45 (m, 4 H), 3.52–3.75 (m, 4 H), 4.02–4.25 (m, 2 H), 8.78–9.32 (m, 2 H), 9.62–9.85 (m, 1 H). Step 3. 4-(1-(2-(Azepan-1-yl)­acetyl)­pyrrolidin-3-yl)- N -methylpiperidine-1-carboxamide (1). 2-(Azepan-1-yl)-1-(3-(piperidin-4-yl)­pyrrolidin-1-yl)­ethan-1-one, Hydrochloride (50 mg, 0.15 mmol) and N-methyl-1H-imidazole-1-carboxamide (22.76 mg, 0.18 mmol) were dissolved in Dichloromethane (DCM) (3 mL). Triethylamine (0.05 mL, 0.38 mmol) was added and the reaction mixture was stirred at room temperature for 18 h. The solvent was removed under reduced pressure and the crude was dissolved in 1.1 mL of MeOH/DMSO (1/0.1) and purified by preparative HPLC. The fractions containing product were collected and the solvents evaporated in vacuo to yield 13.7 mg (26%) of product 1 as a colorless sticky oil. LCMS of the isolated product showed the desired product [M + H]+ = 351; UV = 100%, Rt = 0.59 min (Acquity UPLC BEH C18, 5–100 Acid, 2 min). 1H NMR (400 MHz, DMSO-d 6) δ ppm 0.94–1.13 (m, 2 H), 1.22–1.35 (m, 1 H), 1.35–1.47 (m, 1 H), 1.48–1.60 (m, 9 H), 1.64 (br d, J = 12.63 Hz, 1 H), 1.72–1.82 (m, 1 H), 1.83–1.97 (m, 1 H), 1.97–2.07 (m, 1 H), 2.54 (dd, J = 4.29, 0.76 Hz, 4 H), 2.57–2.65 (m, 5 H), 2.77–2.89 (m, 1 H), 3.03–3.16 (m, 1 H), 3.20 (d, J = 1.52 Hz, 2 H), 3.41–3.59 (m, 1 H), 3.66 (t, J = 8.72 Hz, 1 H), 3.73 (dd, J = 10.23, 7.45 Hz, 1 H), 3.83–4.04 (m, 2 H), 6.34 (br d, J = 3.79 Hz, 1 H). Preparation of N-(4-(1-(cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­propionamide (2). 2-Chloro-1-(1-(cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­ethan-1-one (10a, 100 mg, 0.36 mmol, 1.0 equiv) and N-carbamothioylpropionamide (71.4 mg, 0.54 mmol, 1.5 equiv) were dissolved in ethanol (2.0 mL). The reaction was heated under microwave irradiation at 80 °C for 30 min. The solvent was removed under reduced pressure, and the crude was purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 41.6 mg (48%) of product 2. LCMS of the solid showed the desired product [M + H]+ = 355, UV = 100.0%, Rt = 1.21 min (Acquity UPLC BEH C18, 5–100 Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ ppm 0.78–0.86 (m, 2 H), 0.90–0.96 (m, 2 H), 1.11 (t, J = 7.50 Hz, 3 H), 1.90 (quin, J = 6.50 Hz, 2 H), 1.96–2.05 (m, 1 H), 2.46 (q, J = 7.50 Hz, 2 H), 2.78 (t, J = 6.50 Hz, 2 H), 3.75 (t, J = 6.38 Hz, 2 H), 7.47 (d, J = 8.25 Hz, 1 H), 7.71 (dd, J = 8.38, 2.13 Hz, 1 H), 7.75 (d, J = 2.00 Hz, 1 H), 12.19 (br s, 1 H); 13C NMR (101 MHz, DMSO-d 6) δ 172.71, 172.63, 158.38, 148.79, 138.68, 132.74, 130.96, 126.26, 124.97, 123.63, 107.63, 43.71, 28.70, 27.05, 24.08, 13.72, 9.61, 9.04. Preparation of 6-(5-chlorothiophen-2-yl)-9H-purin-2-amine (3). Step 1. 6-Chloro-N,9-bis­(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine. 3,4-Dihydro-2H-pyran (2.69 mL, 29.5 mmol) was added to 6-chloro-9H-purin-2-amine (500 mg, 2.95 mmol) in anhydrous N,N-Dimethylformamide (DMF, 25 mL) followed by the addition of aqueous HCl (0.05 mL, 0.30 mmol). The mixture was stirred at 60 °C for 2 h. The mixture was evaporated in vacuo, and the crude product was purified by flash column chromatography eluting with CH/EtOAc 0–40% (SiliCycle 80 g, 21 CV) delivering 325 mg (33%) of product as a yellowish sticky oil. LCMS [M + H]+ 338; 1H NMR (400 MHz, DMSO-d 6) δ ppm 1.38–1.50 (m, 3 H), 1.55–1.62 (m, 3 H), 1.71 (br dd, J = 8.88, 3.13 Hz, 2 H), 1.87 (br d, J = 3.75 Hz, 1 H), 1.92–2.00 (m, 2 H), 2.21–2.35 (m, 1 H), 3.46 (td, J = 10.88, 3.00 Hz, 1 H), 3.56–3.73 (m, 1 H), 3.77–3.92 (m, 1 H), 3.93–4.13 (m, 1 H), 5.06–5.26 (m, 1 H), 5.43–5.63 (m, 1 H), 5.67–5.78 (m, 1 H), 8.12 (br d, J = 8.00 Hz, 1 H), 8.41 (s, 1 H). Step 2. 6-(5-Chlorothiophen-2-yl)-N,9-bis­(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine. 6-Chloro-N,9-bis­(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (30 mg, 0.09 mmol), (5-chlorothiophen-2-yl)­boronic acid (17.3 mg, 0.11 mmol), and Pd­(PPh3)2Cl2 (6.23 mg, 0.089 mmol) were dissolved in previously degassed Tetrahydrofuran (THF, 1.0 mL) and saturated NaHCO3 (0.5 mL). The reaction mixture was heated in a sealed tube at 80 °C for 1 h. After 1 h, 1.2 mmol extra of (5-chlorothiophen-2-yl)­boronic acid were added dissolved in THF (0.5 mL) and the reaction was continued heating for 21 h. The reaction mixture was treated with water (5 mL), extracted with EA (3 × 10 mL), washed with brine (10 mL), and dried over anhydrous Na2SO4. The solvent was evaporated under vacuum, and the product was purified by flash column chromatography eluting with CH/EtOAc, 0–40% (SiliCycle 4 g, 24 CV) delivering 25.2 mg (68%) of reaction product as a yellowish sticky oil. LCMS [M + H]+ 420; 1H NMR (400 MHz, chloroform-d) δ ppm 1.63–1.85 (m, 8 H), 1.94–2.01 (m, 2 H), 2.06–2.12 (m, 2 H), 3.71–3.82 (m, 2 H), 4.06 (br d, J = 11.51 Hz, 1H), 4.11–4.24 (m, 1 H), 5.44 (tdd, J = 9.72, 9.72, 3.81, 2.00 Hz, 1 H), 5.65 (td, J = 9.44, 2.63 Hz, 2 H), 7.03 (d, J = 4.00 Hz, 1 H), 8.00 (s, 1 H), 8.34 (d, J = 4.00 Hz, 1 H). Step 3. 6-(5-Chlorothiophen-2-yl)-9H-purin-2-amine. 6-(5-Chlorothiophen-2-yl)-N,9-bis­(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (50 mg, 0.12 mmol) was dissolved in methanol (2 mL) and treated with a solution of HCl (1 mL, 4.0 mmol) in a 2:1 proportion. The reaction mixture was stirred at room temperature for 1 h. The solvent was removed under reduced pressure, and the crude was dissolved in 1.1 mL of MeOH/DMSO (1/0.1) and purified by preparative HPLC. The fractions containing product were collected, and the solvents were evaporated in vacuo to yield 14.4 mg (48%) of product 3 as a yellow solid. LCMS of the solid showed the desired product [M + H]+ = 252; UV = 100%, Rt = 0.96 min (Acquity UPLC BEH C18, 5–100 Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ ppm 6.42 (s, 2 H), 7.28 (d, J = 4.00 Hz, 1 H), 8.13 (s, 1 H), 8.34 (d, J = 4.00 Hz, 1 H), 12.70 (brs, 1 H); 13C NMR (101 MHz, DMSO-d6) δ = 160.43, 155.67 (br s, 1C), 147.87, 141.84 (br d, J = 1.5 Hz, 1C), 140.48, 132.96, 131.68, 129.00, 122.25. Preparation of 6-(2-(2-Methyl-5,8-dihydropyrido­[3,4- d ]­pyrimidin-7­(6H)-yl)­ethoxy)-3,4-dihydroquinolin-2­(1H)-one (4). Step 1. 6-(2-Chloroethoxy)-3,4-dihydroquinolin-2­(1H)-one. In a two-armed round bottomed-flask (25 mL), 1-bromo-2-chloroethane (0.255 mL, 3.06 mmol, 5.0 equiv) was added to a boiling solution of 6-hydroxy-3,4-dihydroquinolin-2­(1H)-one (100.0 mg, 0.61 mmol, 1.0 equiv) and potassium carbonate (127.0 mg, 0.92 mmol, 1.5 equiv) in isopropanol (5 mL), and the reaction mixture was refluxed for 16 h. The hot reaction mixture was diluted with EtOH (10 mL), and the precipitated materials were filtered off via vacuum. The filtrate was cooled on ice. Recrystallization from EtOH (10 mL) gave the titled intermediate 6-(2-chloroethoxy)-3,4-dihydroquinolin-2­(1H)-one (61.0 mg, 0.270 mmol, 44%) as a white solid. LCMS: 227 [M + H]+; 1H NMR (DMSO-d 6, 400 MHz) δ 9.93 (s, 1H), 6.83 (d, 1H, J = 1.0 Hz), 6.8–6.8 (m, 2H), 4.2–4.2 (m, 2H), 3.9–3.9 (m, 2H), 2.84 (t, 2H, J = 7.6 Hz), 2.4–2.4 (m, 2H). Step 2. In a two-armed round bottomed-flask (25 mL), a suspension of 6-(2-chloroethoxy)-3,4-dihydroquinolin-2­(1H)-one (37.0 mg, 0.16 mmol, 1.0 equiv) and sodium iodide (36.9 mg, 0.25 mmol, 1.5 equiv), triethylamine (69 μL, 0.492 mmol, 3.0 equiv) in acetonitrile (5 mL) was refluxed for 4 h, then 2-methyl-5,6,7,8-tetrahydropyrido­[3,4-d]­pyrimidine (61.2 mg, 0.41 mmol, 2.5 equiv) was added to the suspension, and the mixture was refluxed further for 15 h. The solvent was removed under reduced pressure. The residue was diluted with water (5 mL), extracted with DCM (3 × 5 mL), and the extracts were washed with brine (1 × 10 mL), dried over anhydrous MgSO4, and evaporated to dryness to give the crude product as a yellow oil. Purification by prep-HPLC afforded product 4 (15.6 mg, 0.046 mmol, 28%) as a sticky brown oil. LCMS: 339 [M + H]+; 1H NMR (Methanol-d4, 400 MHz) δ 8.46 (s, 1H), 6.8–6.9 (m, 1H), 6.81 (d, 2H, J = 1.5 Hz), 4.20 (t, 2H, J = 5.3 Hz), 3.82 (s, 2H), 3.04 (t, 2H, J = 5.3 Hz), 2.9–3.0 (m, 2H), 2.9–2.9 (m, 4H), 2.63 (s, 3H), 2.5–2.6 (m, 2H); 13C NMR (Methanol-d4, 101 MHz) δ 164.6, 163.4, 156.6, 154.7, 131.2, 125.3, 125.1, 116.0, 114.0, 113.0, 66.0, 56.9, 56.2, 49.7, 30.1, 25.1, 24.1, 23.5. Preparation of N -methyl-6-(4-(2-morpholinoethyl)­piperidin-1-yl)­picolinamide (5). In a two-armed round bottomed-flask (25 mL), to a stirred solution of 4-(2-(piperidin-4-yl)­ethyl)­morpholine (0.103 mL, 0.50 mmol, 1.0 equiv) in dry 1,4-Dioxane (4 mL), cesium carbonate (493.0 mg, 1.5 mmol, 3.0 equiv) followed by 6-chloro-N-methylpicolinamide (68.8 mg, 0.40 mmol, 0.8 equiv) were added. Nitrogen was flushed into the solution for 30 min, and then palladium­(II) acetate (4.53 mg, 0.02 mmol, 0.04 equiv) and BINAP (21.98 mg, 0.035 mmol, 0.07 equiv) were added. The reaction mixture was stirred at 100 °C for 16 h. The resulting reaction mixture (yellow suspension) was filtered through Celite and evaporated under vacuum. Water (5 mL) was added, and the mixture was extracted with EtOAc (3 × 5 mL). The combined organic layers were washed with brine (1 × 5 mL), dried over anhydrous Na2SO4, and evaporated in vacuo. The resulting crude product was purified by prep-HPLC to afford the titled compound 5 (37 mg, 0.111 mmol, 22%) as a brown oil. LCMS: 332 [M + H]+; UV 100%; 1H NMR (Methanol-d4, 400 MHz) δ 7.6–7.7 (m, 1H), 7.3–7.3 (m, 1H), 7.0–7.0 (m, 1H), 4.45 (br d, 2H, J = 13.3 Hz), 3.7–3.7 (m, 4H), 2.96 (s, 3H), 2.8–2.9 (m, 2H), 2.5–2.5 (m, 4H), 2.4–2.5 (m, 2H), 1.8–1.9 (m, 2H), 1.6–1.7 (m, 1H), 1.5–1.6 (m, 2H), 1.26 (dq, 2H, J = 4.0, 12.3 Hz); 13C NMR (Methanol-d4, 101 MHz) δ 166.9, 158.3, 147.4, 138.2, 110.1, 66.2, 56.3, 53.4, 45.1, 34.6, 32.6, 31.7, 25.0. Preparation of 4-chloro-2-methyl-5-((2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)­amino)­pyridazin-3­(2H)-one (6). Step 1. 4,5-Dichloro-2-methylpyridazin-3­(2H)-one. To a flame-dried round-bottom flask (50 mL) were added 4,5-dichloropyridazin-3­(2H)-one (500.0 mg, 3.03 mmol, 1.0 equiv), K2CO3 (838.0 mg, 6.06 mmol, 2.2 equiv), methyl iodide (0.208 mL, 3.33 mmol, 1.1 equiv), and acetonitrile (10 mL). The reaction mixture was refluxed at 80 °C for 16 h, cooled to room temperature, and filtered off using vacuum filtration, and the filtrate was concentrated in vacuo. Additional acetonitrile (10 mL) was used to rinse the flask. Based on LCMS and NMR data, the intermediate was sufficiently pure and was carried forward without further purification. The titled intermediate 4,5-dichloro-2-methylpyridazin-3­(2H)-one obtained in a yield of 459.2 mg (2.57 mmol, 85%) as a dark green solid. Rf = 0.59 (EtOH/EtOAc/Cyclohexenes, 1:3:6, v/v/v). LCMS: 197 [M + H]+; 1H NMR (DMSO-d 6, 400 MHz) δ 8.13 (s, 1H), 3.33 (s, 3H). Step 2. 2-methyl-1,2,3,4-tetrahydroisoquinolin-5-amine (100.0 mg, 0.616 mmol, 1.0 equiv), 4,5-dichloro-2-methylpyridazin-3­(2H)-one (110.0 mg, 0.616 mmol, 1.0 equiv), palladium­(II) acetate (13.84 mg, 0.062 mmol, 0.1 equiv), cesium carbonate (341.0 mg, 1.048 mmol, 1.7 equiv), and BINAP (61.4 mg, 0.099 mmol, 0.16 equiv) were suspended in Toluene (3 mL) and stirred at 80 °C for 5 h. Upon cooling to room temperature, the reaction was diluted in water (10 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL), and the combined organics were washed with sat. aq. sodium hydrogen carbonate (1 × 10 mL), brine (1 × 10 mL), and then evaporated in vacuo to give the crude sample as a brown gum. Purification by prep-HPLC afforded compound 6 (7.5 mg, 0.025 mmol, 4%) as a white solid. Data are in accordance with those previously reported. LCMS: 305 [M + H]+; UV 98%; 1H NMR (DMSO-d 6, 400 MHz) δ 8.37 (s, 1H), 7.66 (s, 1H), 7.08 (t, 1H, J = 1.0 Hz), 6.94 (d, 1H, J = 7.3 Hz), 6.88 (d, 1H, J = 7.8 Hz), 3.67 (s, 3H), 3.48 (s, 2H), 2.63 (t, 2H, J = 1.0 Hz), 2.55 (t, 2H, J = 1.0 Hz), 2.32 (s, 3H); 13C NMR (DMSO-d 6, 101 MHz) δ 156.2, 139.0, 138.4, 137.5, 135.9, 131.4, 125.4, 124.8, 124.6, 108.6, 57.9, 52.6, 46.1, 40.1, 25.7. Hantzsch thiazole synthesis, general procedure C: 9a-9d (1.0 equiv) and an appropriately substituted N-carbamothioyl derivative (1.5 equiv) were dissolved in anhydrous ethanol (1 mL). The reaction mixture was heated under microwave irradiation at 80 °C for 1 h. EtOH solvent was removed under reduced pressure. Purification by prep-HPLC afforded the titled compounds 11a–h, 12b–d, 13, 14, 15a, 15b, 16a, 16b, 17, 18, 26b, 27b, and 28b. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)- N -methylpropionamide (11a). 9a (100 mg, 1.0 equiv, 0.36 mmol) and 1-methylthiourea (48.7 mg, 1.5 equiv, 0.54 mmol) were dissolved in ethanol (2.0 mL). The reaction was heated at 80 °C for 1 h. The solvent was removed, and the crude was passed through a quick column (IIok 4 g, 21 CV 0–80%) isolating 146 mg of crude product that was sequentially used for the propionylation. After column purification, the isolated mixture of methyl thiazole derivatives was dissolved in dry dichloromethane (5.0 mL)/pyridine (1.0 mL) and placed at 0 °C. Triethylamine (72.864 mg, 100 μL, 2.0 equiv, 0.72 mmol) was added followed by dropwise addition of propionyl chloride (66.62 mg, 62.79 μL, 2.0 equiv, 0.72 mmol). The reaction mixture was stirred allowing to warm up to room temperature for 24 h. The solvent was removed under reduced pressure. The crude was dissolved in 1.6 mL of MeOH/DMSO (3/1) and purified by preparative HPLC. The fractions containing product were collected with DCM/MeOH (1/1) and the solvents were evaporated in vacuo to yield 41.0 mg (31%) of 11a as a white solid. LCMS of the isolated solid showed the desired product [M + H]+ = 370.3; UV = 100%, Rt = 1.38 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 7.84–7.73 (m, 2H), 7.59 (s, 1H), 7.47 (d, J = 8.3 Hz, 1H), 3.81–3.68 (m, 5H), 2.84–2.70 (m, 4H), 2.04–1.96 (m, 1H), 1.90 (quin, J = 6.5 Hz, 2H), 1.12 (t, J = 7.3 Hz, 3H), 0.99–0.89 (m, 2H), 0.82 (td, J = 3.1, 7.8 Hz, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 173.98, 172.63, 159.84, 147.86, 138.65, 131.03, 126.12, 124.94, 123.79, 109.21, 43.69, 34.80, 27.72, 27.04, 24.12, 13.79, 9.05, 9.04. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­isobutyramide (11b) and N-(4-(1-(cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-7-yl)­thiazol-2-yl)­isobutyramide (12b). 9a (100 mg, 1.0 equiv, 0.36 mmol) and N-carbamothioylisobutyramide (79 mg, 1.5 equiv, 0.54 mmol) were dissolved in ethanol (2.0 mL). The reaction was heated at 80 °C for 3 h. The solvent was removed under reduced pressure, and the crude was passed through a quick silica gel column (4 g) eluting with CH/EA 0–60% (24 CV). The column delivered 128 mg of a mixture of both thiazole isomers. The crude was dissolved in MeOH and purified by preparative HPLC. The fractions containing product were collected and the solvents evaporated in vacuo to yield: 41.2 mg (31%) of 11b. LCMS showed the desired product [M + H]+ = 370.4, 100% UV, Rt = 1.29 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min), and 29.7 mg (22%) of 12b as a white solid. LCMS showed the same mass [M + H]+ = 370.4, 100% UV at Rt = 1.32 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min). 11a: 1H NMR (400 MHz, DMSO-d 6) δ = 12.20 (s, 1H), 7.76 (d, J = 2.0 Hz, 1H), 7.71 (dd, J = 2.0, 8.3 Hz, 1H), 7.54 (s, 1H), 7.47 (d, J = 8.5 Hz, 1H), 3.76 (t, J = 6.4 Hz, 2H), 2.81–2.72 (m, 3H), 2.04–1.95 (m, 1H), 1.91 (quin, J = 6.5 Hz, 2H), 1.14 (d, J = 6.8 Hz, 7H), 0.97–0.87 (m, 2H), 0.82 (td, J = 3.2, 7.9 Hz, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 175.87, 172.63, 158.45, 148.83, 138.68, 132.74, 130.96, 126.27, 124.97, 123.62, 107.75, 43.71, 34.26, 27.04, 24.08, 19.59, 13.71, 9.04. 12b: 1H NMR (400 MHz, DMSO-d 6) δ = 12.13 (br s, 1H), 7.97 (s, 1H), 7.62 (dd, J = 1.6, 7.9 Hz, 1H), 7.52 (s, 1H), 7.26 (d, J = 8.0 Hz, 1H), 3.77 (t, J = 6.4 Hz, 2H), 2.83–2.71 (m, 3H), 2.07–1.97 (m, 1H), 1.90 (quin, J = 6.5 Hz, 2H), 1.13 (d, J = 6.8 Hz, 6H), 0.96–0.90 (m, 2H), 0.85 (td, J = 3.0, 7.8 Hz, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 175.92, 172.63, 158.47, 148.92, 139.54, 132.65, 132.12, 129.39, 122.27, 122.19, 108.15, 43.68, 34.20, 26.63, 24.09, 19.61, 13.59, 8.97. Cyclopropyl­(6-(2-morpholinothiazol-4-yl)-3,4-dihydroquinolin-1­(2H)-yl)­methanone (11c) and cyclopropyl­(7-(2-morpholinothiazol-4-yl)-3,4-dihydroquinolin-1­(2H)-yl)­methanone (12c). morpholine-4-carbothioamide (39.5 mg, 0.27 mmol, 1.0 equiv) and 9a (50 mg, 0.18 mmol, 1.5 equiv) were dissolved in ethanol (2 mL). The reaction was heated under microwave irradiation at 80 °C for 30 min. We can observe the formation of two overlapping peaks due to the presence of a small amount of the C7-acylated quinoline in the starting material. The solvent was removed under reduced pressure. The crude was dissolved in 0.8 mL of MeOH and purified by preparative HPLC. The fractions containing the product were collected and the solvents evaporated in vacuo to yield 22.2 mg (33%) of 11c (white solid, LCMS showed the desired product at Rt = 1.34 min: [M + H]+ = 370.2 with a 100% purity by UV (Acquity UPLC BEH C18; 5–100%, Acid, 2 min) and 13.4 mg (20%) of 12c (white solid, LCMS showed the desired product at Rt = 1.37 min: [M + H]+ = 370.2 with a 93% purity by UV (Acquity UPLC BEH C18; 5–100%, Acid, 2 min). 11c: 1H NMR (400 MHz, DMSO-d 6) δ = 7.71 (d, J = 1.5 Hz, 1H), 7.70–7.66 (m, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.25 (s, 1H), 3.80–3.67 (m, 6H), 3.50–3.40 (m, 4H), 2.76 (t, J = 6.6 Hz, 2H), 2.03–1.93 (m, 1H), 1.89 (quin, J = 6.5 Hz, 2H), 0.97–0.90 (m, 2H), 0.87–0.75 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.61, 171.14, 150.66, 138.49, 131.30, 126.18, 124.79, 123.76, 102.59, 65.90, 48.64, 43.66, 27.01, 24.11, 13.76, 9.03. 12c: 1H NMR (400 MHz, DMSO-d 6) δ = 7.96 (d, J = 1.5 Hz, 1H), 7.58 (dd, J = 1.6, 7.9 Hz, 1H), 7.30–7.16 (m, 2H), 3.85–3.67 (m, 7H), 3.54–3.39 (m, 4H), 2.74 (t, J = 6.6 Hz, 2H), 2.02–1.94 (m, 1H), 1.88 (quin, J = 6.6 Hz, 2H), 1.02–0.91 (m, 2H), 0.87–0.76 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.55, 171.14, 150.63, 139.35, 132.93, 132.00, 129.16, 122.23, 122.16, 103.00, 65.88, 48.63, 43.41, 26.63, 24.09, 14.02, 8.97. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­benzamide (11d) and N-(4-(1-(cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-7-yl)­thiazol-2-yl)­benzamide (12d). 9a (100 mg, 1.0 equiv, 0.36 mmol) and N-carbamothioylbenzamide (97.3 mg, 1.5 equiv, 0.54 mmol) were dissolved in Ethanol (2.0 mL). The reaction was heated at 80 °C for 3 h. The solvent was removed under reduced pressure, the crude was dissolved in 1.8 mL of MeOH/DMSO (3/1) and purified by preparative HPLC. The fractions containing product were collected with DCM/MeOH (1/1) and the solvents evaporated in vacuo to yield 105.9 mg of a mixture of 2 products. The mixture was repurified by SFC delivering 59.4 mg (41%) of 11d and 13.9 mg (10%) of 12d. 11d: LCMS [M + H]+ = 404.3, UV 100%, Rt = 1.38 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.76 (s, 1H), 8.17–8.11 (m, 2H), 7.83 (d, J = 1.8 Hz, 1H), 7.77 (dd, J = 2.0, 8.5 Hz, 1H), 7.70–7.63 (m, 2H), 7.62–7.54 (m, 2H), 7.50 (d, J = 8.3 Hz, 1H), 3.77 (t, J = 6.3 Hz, 2H), 2.80 (t, J = 6.5 Hz, 2H), 2.08–1.97 (m, 1H), 1.92 (quin, J = 6.5 Hz, 2H), 0.97–0.91 (m, 2H), 0.86–0.80 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.65, 165.68, 158.92, 149.23, 138.74, 133.09, 132.72, 132.45, 130.96, 129.06, 128.65, 126.40, 124.99, 123.74, 108.39, 43.72, 27.04, 24.10, 13.73, 9.05. 12d: LCMS [M + H]+ = 404.3, UV 100%, Rt = 1.40 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.72 (br d, J = 1.3 Hz, 1H), 8.16–8.09 (m, 2H), 8.03 (s, 1H), 7.74–7.50 (m, 5H), 7.29 (d, J = 8.0 Hz, 1H), 3.79 (t, J = 6.3 Hz, 2H), 2.77 (t, J = 6.6 Hz, 2H), 2.09–2.00 (m, 1H), 1.91 (quin, J = 6.6 Hz, 2H), 0.98–0.92 (m, 2H), 0.90–0.82 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.68, 152.40, 152.01, 139.58, 133.06, 129.42, 129.04, 128.66, 122.43, 122.30, 108.77, 26.64, 24.10, 13.60, 8.97. Cyclopropyl­(6-(2-((3,5-dichloropyridin-2-yl)­amino)­thiazol-4-yl)-3,4-dihydroquinolin-1­(2H)-yl)­methanone (11e). 1-(3,5-Dichloropyridin-2-yl)­thiourea (60.0 mg, 0.27 mmol, 1.0 equiv) and 9a (50 mg, 0.18 mmol, 1.5 equiv) were dissolved in ethanol (2 mL). The reaction was heated under microwave irradiation at 80 °C for 2 h. Formation of a solid was observed when reaction cool down. The solid was collected by filtration and washed with MeOH and DCM delivering 31.9 mg of the desired product as a white solid. The rest of the crude was dissolved in 0.4 mL DMSO, 1.0 mL MeOH, and 0.3 mL MeCN and purified by preparative HPLC. The fractions containing product were collected and the solvents evaporated in vacuo to yield 5.2 mg of product. The reaction delivered a total of 44.3 mg of product 11e (55%) as a white solid. LCMS of the solid showed the desired product at Rt = 1.67 min: [M + H]+ = 445.1/[M + H]− = 443.1 with a 100% purity by UV (Acquity UPLC BEH C18; 5–100%, Acid, 2 min). A total of 44.3 mg (55%) of product 11e; 1H NMR (400 MHz, DMSO-d 6DMSO-d 6) δ = 8.41 (d, J = 2.3 Hz, 1H), 8.19 (d, J = 2.3 Hz, 1H), 7.83 (d, J = 1.8 Hz, 1H), 7.76 (dd, J = 2.0, 8.3 Hz, 1H), 7.51 (s, 1H), 7.48 (d, J = 8.5 Hz, 1H), 3.76 (t, J = 6.4 Hz, 2H), 2.79 (t, J = 6.6 Hz, 2H), 2.04–1.96 (m, 1H), 1.91 (quin, J = 6.5 Hz, 2H), 0.97–0.89 (m, 2H), 0.86–0.77 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 182.07, 172.63, 159.53, 143.38, 138.69, 138.00, 132.63, 126.40, 124.90, 123.69, 122.53, 106.95, 43.73, 27.02, 24.10, 13.73, 9.05. 2,4-Dichloro-N-(4-(1-(cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­benzamide (11f). N-Carbamothioyl-2,4-dichlorobenzamide (67.3 mg, 0.27 mmol, 1.0 equiv) and 9a (50 mg, 0.18 mmol, 1.5 equiv) were dissolved in ethanol (2 mL). The reaction was heated under microwave irradiation at 80 °C for 5 h. The solvent was removed under reduced pressure. The crude product was dissolved in 0.5 mL DMSO, 1.0 mL MeOH, and 0.5 mL MeCN and purified by preparative HPLC. The fractions containing the product were collected with DCM/MeOH (1/1) and the solvents were evaporated in vacuo to yield 16.7 mg (19%) of pure product 11f as a white solid (LCMS of the solid showed the desired product at Rt = 1.47 min: [M + H]+ = 472.1/[M–H]− = 470.1 with a 99% purity by UV (Acquity UPLC BEH C18; 5–100%, Acid, 2 min) and 25 mg of a nonseparated mixture of 2 products; 1H NMR (400 MHz, DMSO-d 6) δ = 12.92 (s, 1H), 7.80 (d, J = 2.0 Hz, 1H), 7.79–7.70 (m, 3H), 7.69 (s, 1H), 7.58 (dd, J = 2.0, 8.3 Hz, 1H), 7.48 (d, J = 8.3 Hz, 1H), 3.76 (t, J = 6.3 Hz, 2H), 2.79 (t, J = 6.6 Hz, 2H), 2.05–1.96 (m, 1H), 1.91 (quin, J = 6.4 Hz, 2H), 0.98–0.88 (m, 2H), 0.85–0.75 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.66, 164.57, 157.93, 149.25, 138.81, 136.22, 133.64, 132.09, 131.38, 130.73, 129.85, 127.92, 126.34, 125.01, 123.74, 108.55, 43.73, 27.04, 24.07, 13.73, 9.06. Cyclopropyl­(6-(2-((2,4-dichlorophenyl)­amino)­thiazol-4-yl)-3,4-dihydroquinolin-1­(2H)-yl)­methanone (11g). 1-(2,4-Dichlorophenyl)­thiourea (59.7 mg, 0.27 mmol, 1.0 equiv) and 9a (50 mg, 0.180 mmol, 1.5 equiv) were dissolved in ethanol (2 mL). The reaction was heated under microwave irradiation at 80 °C for 30 min. The solvent was removed under reduced pressure. The crude was suspended with MeOH. A solid was formed, collected by filtration, and washed with MeOH and DCM delivering 17.1 mg (21%) of the desired product 11g. The rest of the crude was dissolved in 1.3 mL of MeOH/DMSO (4/1) and purified by preparative HPLC. The fractions containing product were collected and the solvents evaporated in vacuo to yield 32.3 mg of a nonseparated mixture of isomers; LCMS [M + H]+ = 444.1, UV 99%, Rt = 1.66 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 9.81 (s, 1H), 8.57 (d, J = 9.1 Hz, 1H), 7.76–7.68 (m, 2H), 7.63 (d, J = 2.5 Hz, 1H), 7.50–7.42 (m, 2H), 7.37 (s, 1H), 3.74 (br t, J = 6.4 Hz, 2H), 2.78 (t, J = 6.6 Hz, 2H), 1.98 (qd, J = 4.1, 8.1 Hz, 1H), 1.90 (quin, J = 6.4 Hz, 2H), 0.97–0.89 (m, 2H), 0.87–0.76 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.63, 163.53, 149.75, 138.57, 137.26, 131.05, 129.31, 128.35, 126.17, 126.07, 124.90, 123.82, 123.08, 122.06, 104.87, 43.68, 27.06, 24.12, 13.78, 9.05. (6-(2-Aminothiazol-4-yl)-3,4-dihydroquinolin-1­(2H)-yl)­(cyclopropyl)­methanone (11h). 9a (500 mg, 1.0 equiv, 1.8 mmol) and thiourea (205.5 mg, 1.5 equiv, 2.7 mmol) were dissolved in a microwave vial in ethanol (10 mL). The reaction mixture was heated at 80 °C for 30 min. The solvent was removed under reduced pressure, the crude was dissolved in 1.8 mL of MeOH/DMSO (3/2) and purified by preparative HPLC. The fractions containing product were collected with DCM/MeOH (1/1), and the solvents evaporated in vacuo to yield 359.4 mg (67%) of the desired product 11h (thiazole in position C6). LCMS of the solid showed the desired product [M + H]+ = 300.4; UV= 100%, Rt = 1.55 min (XBRIDGE C18 3.5 μm; 4.6 × 50 mm at 40 °C; 30–100% (Water 5 mM ammonium bicarbonate/Acetonitrile), 5 min at 1 mL/min). Separation also yielded 43.2 mg (7%) of the aminothiazole derivative in position C7. 1H NMR (400 MHz, DMSO-d 6) δ = 7.65 (s, 1H), 7.61 (dd, J = 2.0, 8.3 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.07–7.00 (m, 2H), 6.95 (s, 1H), 3.73 (t, J = 6.4 Hz, 2H), 2.75 (t, J = 6.5 Hz, 2H), 2.04–1.94 (m, 1H), 1.89 (quin, J = 6.6 Hz, 2H), 0.94–0.87 (m, 2H), 0.85–0.77 (m, 2H). Amination Compounds 12i-12o General procedure D: Amine 11h (1.0 equiv) was dissolved under nitrogen in dry dichloromethane (2.0 mL). Pyridine (1.5 equiv) was added, followed by the corresponding acyl chloride (1.2–1.5 equiv). The reaction mixture was stirred at room temperature until the reaction was completed as indicated by LCMS. The solvent was removed under a reduced pressure. The crude mixture was dissolved in DMSO/MeCN and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield the desired product. General procedure E: Amine 11h (1.0 equiv) and sulfonyl chloride (1.5 equiv) were dissolved in anhydrous DCM/Pyridine (2:1) at 0 °C. The reaction mixture was stirred at room temperature until the reaction was complete, as indicated by LCMS. The solvent was removed under reduced pressure, the crude product was dissolved in MeOH/DMSO and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield the desired product. General Procedure F: Amine 11h (1 equiv) was dissolved under nitrogen in dry DMF (2.0 mL) at 0 °C. Triethylamine (2.5 equiv) was added, followed by the carboxylic acid derivative (2.0 equiv). The reaction mixture was stirred at 60 °C until the reaction was complete, as indicated by LCMS. Water was added and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in MeOH/DMSO and purified by preparative HPLC. The fractions containing the product were collected and the solvents were evaporated in vacuo to yield the desired product. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­cyclobutanecarboxamide (11j). Following general procedure D, 11h (20.0 mg, 1.0 equiv, 0.067 mmol) was dissolved under nitrogen in dry DCM (2.0 mL). Pyridine (7.9 mg, 8.10 μL, 1.5 equiv, 0.1 mmol) was added, followed by cyclobutanecarbonyl chloride (9.5 mg, 9.1 μL, 1.2 equiv, 0.08 mmol). The reaction mixture was stirred at room temperature for 1 h. After the reaction was completed, as indicated by LCMS, the solvent was removed under reduced pressure. The crude was dissolved in DMSO/MeCN (1/2) and purified by preparative HPLC. The fractions containing the product were collected with DCM/MeOH (1/1) and the solvents were evaporated in vacuo to yield 23.2 mg (90%) of 11j as a white solid. LCMS of the isolated solid showed the desired product [M + H]+ = 382.3; UV = 99%, Rt = 1.32 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.10 (s, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.70 (dd, J = 2.1, 8.4 Hz, 1H), 7.54 (s, 1H), 7.46 (d, J = 8.3 Hz, 1H), 3.75 (t, J = 6.4 Hz, 2H), 3.44–3.34 (m, 1H), 2.78 (t, J = 6.6 Hz, 2H), 2.35–2.09 (m, 4H), 2.06–1.77 (m, 5H), 0.97–0.88 (m, 2H), 0.87–0.75 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 173.49, 172.63, 158.46, 148.84, 138.68, 132.73, 130.96, 126.27, 124.96, 123.62, 107.74, 43.70, 38.73, 27.04, 24.93, 24.08, 18.24, 13.71, 9.04. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)-4,4-difluorocyclohexane-1-carboxamide (11l). Following general procedure D, 11h (25.0 mg, 1.0 equiv, 0.083 mmol) was dissolved under nitrogen in dry DCM (2.0 mL). Pyridine (9.91 mg, 10.1 μL, 1.5 equiv, 0.125 mmol) was added, followed by 4,4-difluorocyclohexane-1-carbonyl chloride (30.5 mg, 24.4 μL, 2.0 equiv, 0.167 mmol). The reaction mixture was stirred at room temperature for 2 h. After the reaction was completed as indicated by LCMS, the solvent was removed under reduced pressure, and the crude was dissolved in DMSO/MeOH (1/3) and purified by preparative HPLC. The fractions containing the product were collected with DCM/MeOH (1/1) and the solvents evaporated in vacuo to yield 33.1 mg (89%) of desired product 11l as a white solid. LCMS of the isolated solid showed the desired product [M + H]+ = 446.4; UV = 100%, Rt = 1.36 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.33 (br s, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.71 (dd, J = 2.0, 8.5 Hz, 1H), 7.56 (s, 1H), 7.47 (d, J = 8.3 Hz, 1H), 3.76 (t, J = 6.4 Hz, 2H), 2.78 (t, J = 6.6 Hz, 2H), 2.73–2.62 (m, 1H), 2.19–2.06 (m, 2H), 2.04–1.61 (m, 10H), 0.98–0.89 (m, 2H), 0.87–0.77 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 173.55 (d, J = 2.2 Hz, 1C), 172.64, 158.27, 148.87, 138.71, 132.75, 130.90, 126.38, 126.27, 124.98, 123.98, 123.64, 121.60, 107.87, 43.71, 41.06, 32.70 (d, J = 24.7 Hz, 1C), 32.34, 27.04, 25.72 (d, J = 9.4 Hz, 1C), 24.08, 13.72, 9.04. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)-3,3-difluorobutanamide (11m). Following general procedure F, 3,3-difluorobutanoic acid (16.6 mg, 2.0 equiv, 0.13 mmol) was dissolved under nitrogen in dry DMF (2.0 mL). Triethylamine (17 mg, 23.3 μL, 2.5 equiv, 0.17 mmol) was added, followed by O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) (47.2 mg, 2.2 equiv, 0.15 mmol). The reaction mixture was stirred for 30 min followed by the addition of 11h (20 mg, 1.0 equiv, 0.07 mmol). The reaction mixture was stirred at 60 °C for 24 h. Water was added, and the reaction mixture was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude product was dissolved in MeOH/DMSO (5:1) and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 5.4 mg of the desired product 11m (20%) as a white solid. LCMS of the isolated product showed the desired product [M + H]+ = 406.2, 100% purity by UV, Rt = 1.30 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.51 (br s, 1H), 7.76 (d, J = 1.8 Hz, 1H), 7.72 (dd, J = 2.0, 8.5 Hz, 1H), 7.61 (s, 1H), 7.48 (d, J = 8.5 Hz, 1H), 3.76 (t, J = 6.4 Hz, 2H), 3.23 (t, J = 15.0 Hz, 2H), 2.79 (t, J = 6.6 Hz, 2H), 2.05–1.96 (m, 1H), 1.91 (quin, J = 6.4 Hz, 2H), 1.79 (t, J = 19.4 Hz, 3H), 0.96–0.89 (m, 2H), 0.87–0.78 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ = 172.65, 165.52–165.15 (m, 1C), 157.79, 148.97, 138.79, 132.79 (br s, 1C), 130.76, 126.30, 125.32, 125.00, 123.66, 122.95, 120.57, 108.15, 43.71, 43.72 (d, J = 54.5 Hz, 1C), 27.05, 24.07, 23.74, 23.74 (br d, J = 52.3 Hz, 1C), 13.73, 9.05. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)-2,2-difluoropropane-1-sulfonamide (11n). Following general procedure E, 11h (50 mg, 0.167 mmol, 1.0 equiv) and 2,2-difluoropropane-1-sulfonyl chloride (59.6 mg, 0.33 mmol, 1.5 equiv) were dissolved in anhydrous dichloromethane (DCM, 2.0 mL) and pyridine (1.0 mL) at 0 °C. The reaction was stirred at room temperature for 20 h. The solvent was removed under reduced pressure, and the crude was dissolved in MeOH/DMSO (3/1) and purified by preparative HPLC. The fractions containing the product were collected with DCM/MeOH (1/1), and the solvents were evaporated in vacuo to yield 52.5 mg of the impure desired product. The solid was repurified by SFC delivering 23.1 mg (31%) of 11n as a white solid. LCMS [M + H]+ = 442, UV 95% purity; 1H NMR (400 MHz, DMSO-d 6) δ = 13.50–12.92 (m, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.62–7.54 (m, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.14 (s, 1H), 3.87–3.72 (m, 4H), 2.76 (t, J = 6.5 Hz, 2H), 2.02–1.94 (m, 1H), 1.90 (t, J = 6.4 Hz, 2H), 1.86 (s, 3H), 1.17 (t, J = 7.4 Hz, 1H), 1.06 (t, J = 7.0 Hz, 1H), 0.96–0.90 (m, 2H), 0.83 (td, J = 3.1, 7.8 Hz, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 199.38, 172.75, 139.41, 132.84, 126.19, 124.95, 123.80, 123.55, 121.41, 103.16 (br d, J = 1.5 Hz, 1C), 57.79 (t, J = 27.6 Hz, 1C), 56.49, 43.84, 41.85, 27.00, 23.95, 23.88, 23.62, 23.37, 19.04, 13.76, 11.53, 9.10. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­ethanesulfonamide (11o). Following general procedure E, 11h (30.0 mg, 1.0 equiv, 0.1 mmol) was dissolved under argon in dry dichloromethane (2.0 mL) and pyridine (0.2 mL) at 0 °C. Triethylamine (20.3 mg, 27.9 μL, 2.0 equiv, 0.20 mmol) was added, followed by ethanesulfonyl chloride (25.8 mg, 18.99 μL, 2.0 equiv, 0.24 mmol). The reaction mixture was stirred and allowed to warm up to room temperature for 19 h. The solvent was removed under reduced pressure, and the crude product was purified by preparative HPLC. The fractions containing the product were collected, and the solvents evaporated in vacuo to yield 16.9 mg of product 11o (43%) as a white solid. LCMS of the isolated solid showed the desired product [M + 1]+ = 392.2, 99% purity by UV, Rt = 1.09 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 13.12–12.70 (m, 1H), 7.64 (d, J = 1.5 Hz, 1H), 7.60–7.55 (m, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.13 (br s, 1H), 3.76 (t, J = 6.4 Hz, 2H), 3.07 (br d, J = 7.0 Hz, 2H), 2.76 (t, J = 6.6 Hz, 2H), 2.02–1.95 (m, 1H), 1.94–1.86 (m, 2H), 1.23 (t, J = 7.3 Hz, 3H), 0.98–0.90 (m, 2H), 0.88–0.77 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.78, 139.66, 132.89, 126.16, 125.00, 123.49, 99.99, 47.60, 43.89, 26.99, 23.92, 13.77, 9.12, 8.73. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­acrylamide (11p). Following general procedure D, 11h (25.0 mg, 1 equiv, 0.084 mmol) was dissolved under nitrogen in dry dichloromethane (2.0 mL) at 0 °C. Triethylamine (16.9 mg, 23.3 μL, 2.0 equiv, 0.17 mmol) was added, followed by acryloyl chloride (15.12 mg, 13.57 μL, 2.0 equiv, 0.17 mmol). The reaction mixture was stirred and allowed to warm up to room temperature for 1 h. The solvent was removed under reduced pressure, and the crude product was dissolved in 1.3 mL MeOH and 0.5 mL DMSO. Then, it was purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 7 mg (24%) of 11p as a white solid. LCMS of the isolated solid showed the product [M + H]+ = 354.1, UV= 100%, Rt = 1.24 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.51 (br s, 1H), 7.77 (d, J = 2.0 Hz, 1H), 7.73 (dd, J = 2.1, 8.4 Hz, 1H), 7.61 (s, 1H), 7.48 (d, J = 8.3 Hz, 1H), 6.63–6.50 (m, 1H), 6.47–6.38 (m, 1H), 5.97–5.86 (m, 1H), 3.76 (t, J = 6.4 Hz, 2H), 2.79 (t, J = 6.5 Hz, 2H), 2.04–1.96 (m, 1H), 1.91 (quin, J = 6.4 Hz, 2H), 0.95–0.90 (m, 2H), 0.87–0.78 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.65, 163.54, 158.32, 149.20, 138.76, 130.85, 130.01, 129.81, 126.30, 125.00, 123.66, 108.42, 43.73, 27.06, 24.08, 13.73, 9.05. 2-Chloro-N-(4-(1-(cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­acetamide (11q). Following general procedure D, 11h (25.0 mg, 1 equiv, 0.084 mmol) was dissolved under nitrogen in dry dichloromethane (2.0 mL) at 0 °C. Triethylamine (16.9 mg, 23.3 μL, 2.0 equiv, 0.17 mmol) was added, followed by chloroacetyl chloride (18.9 mg, 13.29 μL, 2.0 equiv, 0.17 mmol). The reaction mixture was stirred allowing to warm up to room temperature for 1 h. The solvent was removed under reduced pressure. The crude product was dissolved in 1.8 mL of MeCN/DMSO (3/1) and purified by preparative HPLC. The fractions containing the product were collected with DCM/MeOH (1/1), and the solvents evaporated in vacuo to yield 13.7 mg (43%) of 11q as a white solid. LCMS of the isolated solid showed the desired product [M + H]+ = 376.1; UV = 100%, Rt = 1.26 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.64 (br s, 1H), 7.76 (d, J = 1.8 Hz, 1H), 7.72 (dd, J = 2.0, 8.3 Hz, 1H), 7.63 (s, 1H), 7.48 (d, J = 8.5 Hz, 1H), 4.41 (s, 2H), 3.76 (t, J = 6.4 Hz, 2H), 2.79 (t, J = 6.6 Hz, 2H), 2.06–1.95 (m, 1H), 1.91 (quin, J = 6.5 Hz, 2H), 0.98–0.89 (m, 2H), 0.88–0.76 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.66, 165.56, 157.83, 149.15, 138.82, 132.82, 130.70, 126.30, 125.01, 123.68, 108.41, 43.72, 42.76, 27.06, 24.07, 13.74, 9.05. Compounds 11i, 11k, 11r, 11s, 11t, 11u, 11v, 11w, and 11x were available and evaluated from the GSK library. LCMS and purity and included in the Supporting Information 2,2′-(Ethane-1,2-diylbis­(oxy))­bis­(N-(4-(1-(cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­acetamide) (11y). 2-[2-(carboxymethoxy)­ethoxy]­acetic acid (20.8 mg, 14.1 μL, 0.7 equiv, 0.11 mmol) and HATU (108 mg, 1.7 equiv, 0.3 mmol) were dissolved under nitrogen in dry DMF (3.0 mL). DIPEA (49 μL, 1.7 equiv, 0.28 mmol) was added, and the reaction mixture was stirred for 20 min at room temperature. 11h (50.0 mg, 1.0 equiv, 0.17 mmol) was sequentially added, and the reaction was continued stirring for 48 h and followed by LCMS. Water was added (10 mL), and the crude was extracted with EA (3 × 10 mL), washed with brine (20 mL), and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure, and the crude was purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 9.5 mg (8%) of compound 11y as a white solid. LCMS of the isolated solid showed the desired product [M + H]+ = 740.0; UV = 100%, Rt = 1.33 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.55–11.47 (m, 2H), 7.73 (d, J = 1.8 Hz, 2H), 7.69 (dd, J = 2.1, 8.4 Hz, 2H), 7.57 (s, 2H), 7.43 (d, J = 8.3 Hz, 2H), 4.34 (s, 4H), 3.78 (s, 4H), 3.73 (t, J = 6.4 Hz, 4H), 2.75 (t, J = 6.6 Hz, 4H), 2.02–1.93 (m, 2H), 1.88 (quin, J = 6.5 Hz, 4H), 0.97–0.88 (m, 4H), 0.86–0.75 (m, 4H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.61, 169.28, 157.76, 148.94, 138.69, 132.77, 130.84, 126.26, 124.93, 123.67, 107.97, 70.99, 69.72, 43.66, 27.01, 24.07, 13.71, 9.03. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)-1H-imidazol-2-yl)­acetamide (13). 9a (100.0 mg, 1.0 equiv, 0.36 mmol) and N-carbamimidoylacetamide (109.21 mg, 3.0 equiv, 1.1 mmol) were dissolved under nitrogen in anhydrous acetonitrile (2.0 mL). The reaction was heated under microwave irradiation at 80 °C for 4 h. The solvent was removed under reduced pressure, and the crude was dissolved in 1.8 mL MeOH/DMSO/Water (3/1/0.1), purified by preparative HPLC. The fractions containing the product were collected with DCM/MeOH (1/1), and the solvents were evaporated in vacuo to yield 23.4 mg (20%) of 13 as a pale yellow solid. LCMS of the isolated solid showed the desired product [M + H]+ = 325.3; UV = 100%, Rt = 0.77 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 11.60 (br s, 1H), 11.22 (s, 1H), 7.57 (s, 1H), 7.54 (dd, J = 1.8, 8.3 Hz, 1H), 7.35 (br d, J = 8.3 Hz, 1H), 7.22 (d, J = 1.8 Hz, 1H), 3.72 (br t, J = 6.4 Hz, 2H), 2.73 (t, J = 6.5 Hz, 2H), 2.07 (s, 3H), 2.02–1.93 (m, 1H), 1.88 (quin, J = 6.6 Hz, 2H), 0.94–0.88 (m, 2H), 0.80 (td, J = 3.2, 7.8 Hz, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.46, 168.94, 141.70, 137.08, 136.24, 132.84, 131.56, 124.82, 124.41, 122.00, 109.37, 43.53, 27.00, 24.19, 23.27, 13.61, 8.93. N-(4-(1-(Cyclopropylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­propionamide (14). 9b (58.0 mg, 0.185 mmol, 1.0 equiv) and N-carbamothioylpropionamide (36.65 mg, 0.277 mmol, 1.5 equiv) were dissolved in anhydrous ethanol (1 mL). The reaction mixture was heated under microwave irradiation at 80 °C for 1 h. EtOH solvent was removed under reduced pressure. Purification by prep-HPLC afforded the titled compound 14 (16.2 mg, 0.041 mmol, 24%) as a white solid. LCMS: 392.4 [M + H]+, UV = 100%, Rt = 1.24 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (DMSO-d 6, 400 MHz) δ 12.20 (s, 1H), 7.71 (d, 1H, J = 1.0 Hz), 7.7–7.7 (m, 1H), 7.6–7.6 (m, 1H), 7.53 (s, 1H), 3.7–3.8 (m, 2H), 2.89 (t, 2H, J = 1.0 Hz), 2.7–2.8 (m, 1H), 2.46 (q, 2H, J = 1.0 Hz), 2.0–2.0 (m, 2H), 1.11 (t, 3H, J = 1.0 Hz), 0.9–1.0 (m, 4H); 13C NMR (DMSO-d 6, 101 MHz) δ 172.7, 158.4, 148.6, 137.0, 130.8, 130.5, 127.2, 123.9, 123.8, 107.7, 46.7, 29.8, 28.7, 26.9, 22.4, 9.6, 5.5. N-(4-(1-(Cyclopropanecarbonyl)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­propionamide (15a) and N-(4-(1-(cyclopropanecarbonyl)-2-methyl-1,2,3,4-tetrahydroquinolin-7-yl)­thiazol-2-yl)­propionamide (15b). N-carbamothioylpropionamide (68.0 mg, 0.51 mmol, 1.0 equiv) and 9b (100 mg, 0.34 mmol, 1.5 equiv) were dissolved in anhydrous Ethanol (2 mL). The reaction was heated under microwave irradiation at 80 °C for 1 h. We can observe the formation of two overlapping peaks due to the presence of a small amount of the acylated product in C6 position of the quinoline in the starting material. The solvent was removed under reduced pressure. The crude was passed by a quick silica gel column eluting with CH to CH/EtOAc 0–30%. The crude was purified by preparative HPLC. The fractions containing product were collected, and the solvents were evaporated in vacuo to yield 36.2 mg (29%) of 15a (white solid, LCMS of the isolated solid showed [M + 1]+ = 370.2, 96% UV, Rt = 1.30 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min) and 7.4 mg (6%) of 15b (white solid, LCMS of the isolated solid showed [M + 1]+ = 370.2, 99% UV, Rt = 1.27 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min). 15a: 1H NMR (400 MHz, DMSO-d 6) δ = 12.20 (s, 1H), 7.77 (s, 1H), 7.75 (dd, J = 2.0, 8.3 Hz, 1H), 7.55 (s, 1H), 7.38 (d, J = 8.3 Hz, 1H), 4.68 (sxt, J = 6.7 Hz, 1H), 2.80–2.67 (m, 1H), 2.65–2.54 (m, 1H), 2.49–2.43 (m, 2H), 2.35–2.24 (m, 1H), 1.92–1.79 (m, 1H), 1.46–1.34 (m, 1H), 1.11 (t, J = 7.6 Hz, 3H), 1.07 (d, J = 6.3 Hz, 3H), 1.04–0.96 (m, 1H), 0.92–0.76 (m, 2H), 0.71–0.62 (m, 1H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.73, 172.11, 158.42, 148.80, 137.08, 134.73, 131.46, 126.22, 125.47, 123.93, 107.78, 48.57, 32.14, 28.70, 25.76, 20.39, 13.61, 9.61, 9.50, 8.41. 15b: 1H NMR (400 MHz, DMSO-d 6) δ = 12.14 (s, 1H), 7.89 (d, J = 1.5 Hz, 1H), 7.66 (dd, J = 1.8, 7.8 Hz, 1H), 7.55 (s, 1H), 7.29 (d, J = 7.8 Hz, 1H), 4.70 (sxt, J = 6.8 Hz, 1H), 2.69 (td, J = 5.4, 15.1 Hz, 1H), 2.59–2.53 (m, 1H), 2.49–2.43 (m, 2H), 2.36–2.25 (m, 1H), 1.92–1.81 (m, 1H), 1.35 (dddd, J = 5.1, 7.1, 10.1, 12.7 Hz, 1H), 1.11 (t, J = 7.5 Hz, 3H), 1.06 (d, J = 6.5 Hz, 3H), 1.03–0.95 (m, 1H), 0.95–0.80 (m, 2H), 0.71–0.61 (m, 1H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.74, 172.07, 158.41, 148.75, 137.92, 134.37, 133.05, 128.49, 123.48, 122.74, 108.07, 48.44, 32.26, 28.68, 25.45, 20.45, 13.49, 9.58, 9.50, 8.34. N-(4-(1-Acetyl-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­propionamide (16a) and N-(4-(1-acetyl-1,2,3,4-tetrahydroquinolin-7-yl)­thiazol-2-yl)­propionamide (16b). N-Carbamothioylpropionamide (79 mg, 0.60 mmol) and 9d (100 mg, 0.40 mmol) were dissolved in ethanol (2 mL). The reaction was heated under microwave irradiation at 80 °C for 1.5 h. The solvent was removed under reduced pressure. The crude was passed by a quick silica gel column chromatography eluting with CH to CH/EtOAc 0–20%. The crude was dissolved in 0.5 mL of MeOH and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 27.6 mg (21%) of 16a (white solid, LCMS of the isolated product showed [M + H]+= 330.1, 96% UV, Rt = 1.12 min, Acquity UPLC BEH C18; 5–100%, Acid, 2 min), and 25.0 mg (19%) of 16b (white solid, LCMS of the isolated product showed [M + 1] += 330.1, 95% UV, Rt = 1.08 min, Acquity UPLC BEH C18; 5–100%, Acid, 2 min). 16a: 1H NMR (400 MHz, DMSO-d 6) δ = 12.19 (s, 1H), 7.71 (s, 1H), 7.68 (br d, J = 8.3 Hz, 1H), 7.53 (s, 2H), 3.70 (t, J = 6.3 Hz, 2H), 2.76 (t, J = 6.6 Hz, 2H), 2.46 (q, J = 7.7 Hz, 2H), 2.20 (s, 3H), 1.90 (quin, J = 6.4 Hz, 2H), 1.11 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.70, 169.72, 158.37, 148.82, 126.14, 125.10, 123.48, 107.60, 28.70, 27.09, 23.95, 23.79, 9.61. 16b: 1H NMR (400 MHz, DMSO-d 6) δ = 12.18 (s, 1H), 8.18–7.88 (m, 1H), 7.61 (br d, J = 7.5 Hz, 1H), 7.56 (s, 1H), 7.22 (d, J = 8.0 Hz, 1H), 3.75–3.65 (m, 2H), 2.73 (t, J = 6.6 Hz, 2H), 2.46 (q, J = 7.5 Hz, 2H), 2.21 (s, 3H), 1.89 (quin, J = 6.4 Hz, 2H), 1.11 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.73, 169.69, 158.34, 148.96, 132.54, 129.26, 122.30, 122.18, 107.90, 28.69, 26.64, 23.98, 23.69, 9.61. N-(4-(2-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)­thiazol-2-yl)­propionamide (18). 9e (48.5 mg, 0.17 mmol, 1.0 equiv) and N-carbamothioylpropionamide (34.6 mg, 0.26 mmol, 1.5 equiv) were dissolved in anhydrous ethanol (1.0 mL). The reaction mixture was heated under microwave irradiation at 80 °C for 1.5 h. EtOH solvent was removed under reduced pressure. Purification by prep-HPLC afforded the titled compound 17 (12.5 mg, 0.035 mmol, 20%) as a white solid. LCMS: 356.2 [M + H]+; UV 100%, Rt = 1.15 min, Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (DMSO-d 6, 400 MHz) δ 12.18 (s, 1H), 7.7–7.8 (m, 1H), 7.70 (s, 1H), 7.5–7.6 (m, 1H), 7.24 (br d, 1H, J = 8.0 Hz), 4.6–5.0 (m, 2H), 3.7–4.0 (m, 2H), 2.7–3.0 (m, 2H), 2.46 (q, 2H, J = 7.5 Hz), 2.0–2.1 (m, 1H), 1.11 (t, 3H, J = 1.0 Hz), 0.7–0.8 (m, 4H); 13C NMR (DMSO-d 6, 101 MHz) δ 172.8, 158.5, 149.0, 134.8, 132.9, 129.3, 124.2, 124.0, 107.8, 44.7, 43.2, 29.3, 28.7, 11.1, 9.6, 7.7, 7.4, 7.3. N-(4-(1-(Cyclopropanecarbonyl)­indolin-5-yl)­thiazol-2-yl)­propionamide (18). N-Carbamothioylpropionamide (75 mg, 0.57 mmol, 1.0 equiv) and 9f (100 mg, 0.38 mmol, 1.5 equiv) were dissolved in ethanol (2 mL). The reaction was heated under microwave irradiation at 80 °C for 1.5 h. A solid was formed in the reaction mixture, and it was collected by filtration, washed with MeOH, and dried under vacuum isolating 87.3 mg (67%) of the desired product 18 as a white solid. LCMS: 342.2 [M + H]+, UV 98%, Rt = 1.18 min, Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.16 (s, 1H), 8.05 (br d, J = 8.0 Hz, 1H), 7.75 (s, 1H), 7.69 (dd, J = 1.6, 8.4 Hz, 1H), 7.46 (s, 1H), 4.41–4.27 (m, 2H), 3.23 (br t, J = 8.0 Hz, 2H), 2.48–2.42 (m, 2H), 1.97 (br s, 1H), 1.11 (t, J = 7.5 Hz, 3H), 0.95–0.82 (m, 5H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.66, 171.59, 158.24, 149.17, 143.14, 132.83, 129.98, 125.16, 122.58, 116.33, 106.77, 48.41, 28.70, 27.70, 13.66, 9.62, 8.34. N-(4-(4-(Cyclopropanecarbonyl)-3,4-dihydro-2H-benzo­[b]­[1,4]­oxazin-6-yl)­thiazol-2-yl)­propionamide (26b). 9g (100.0 mg, 1.0 equiv, 0.36 mmol) and N-carbamothioylpropionamide (70.9 mg, 1.5 equiv, 0.54 mmol) were dissolved in ethanol (2.0 mL). The reaction was heated at 80 °C for 3 h. A solid was formed during the reaction. The reaction mixture was cooled down, and the solid was collected by filtration, washed with Et2O (5 mL), and dried under vacuum delivering 60.2 mg (47%) of product 26b as a white solid. LCMS: 358.4 [M + H]+, UV 100%, Rt = 1.16 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.12 (s, 1H), 8.18 (br s, 1H), 7.58 (dd, J = 2.0, 8.5 Hz, 1H), 7.40 (s, 1H), 6.96 (d, J = 8.5 Hz, 1H), 4.36–4.20 (m, 2H), 3.99 (br s, 2H), 2.47 (q, J = 7.5 Hz, 2H), 2.17 (tt, J = 4.9, 7.6 Hz, 1H), 1.10 (t, J = 7.5 Hz, 3H), 1.01–0.85 (m, 4H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.70, 171.78, 158.32, 148.79, 146.46, 127.04, 126.73, 123.27, 121.88, 117.63, 106.74, 66.87, 28.67, 13.32, 9.61, 9.01. N-(4-(4-(Cyclopropanecarbonyl)-3,4-dihydro-2H-benzo­[b]­[1,4]­thiazin-6-yl)­thiazol-2-yl)­propionamide (27b). 9h (100.0 mg, 1.0 equiv, 0.34 mmol) and N-carbamothioylpropionamide (67.0 mg, 1.5 equiv, 0.51 mmol) were dissolved in ethanol (2.0 mL). The reaction was heated at 80 °C for 3 h. A solid formed during the reaction. It was cooled down, and the solid was collected by filtration, washed with Et2O (5 mL), and dried under vacuum delivering 77.4 mg (61%) of 27b as a pale-yellow solid. LCMS: 374.3 [M + H]+, UV 98%, Rt = 1.22 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.15 (s, 1H), 7.91 (d, J = 1.8 Hz, 1H), 7.68 (dd, J = 1.8, 8.3 Hz, 1H), 7.58 (s, 1H), 7.33 (d, J = 8.5 Hz, 1H), 3.97 (br s, 2H), 3.22 (t, J = 5.6 Hz, 2H), 2.47 (q, J = 7.3 Hz, 2H), 2.03–1.88 (m, 1H), 1.11 (t, J = 7.5 Hz, 3H), 0.96–0.90 (m, 2H), 0.84 (td, J = 3.1, 7.8 Hz, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.78, 172.19, 158.48, 148.22, 138.24, 131.31, 128.25, 127.78, 124.20, 123.74, 108.20, 28.80, 28.67, 12.93, 9.58, 9.25. N-(4-(1-(Cyclopropanecarbonyl)-2,3,4,5-tetrahydro-1H-benzo­[b]­azepin-8-yl)­thiazol-2-yl)­propionamide (28b). 9i (100.0 mg, 1.0 equiv, 0.34 mmol) and N-carbamothioylpropionamide (67.9 mg, 1.5 equiv, 0.51 mmol) were dissolved in ethanol (2.0 mL). The reaction was heated at 80 °C for 3 h. A solid was formed during the reaction. The reaction mixture was cooled down, and the solid was collected by filtration, washed with Et2O (5 mL), and dried under vacuum delivering 52 mg (40%) of 28b as a white solid. LCMS: 370.3 [M + H]+, UV 99%, Rt = 1.22 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.17 (s, 1H), 7.82 (d, J = 1.8 Hz, 1H), 7.79 (dd, J = 1.9, 7.9 Hz, 1H), 7.66 (s, 1H), 7.40 (d, J = 7.8 Hz, 1H), 4.65–4.50 (m, 1H), 2.84–2.74 (m, 1H), 2.73–2.54 (m, 2H), 2.49–2.42 (m, 2H), 1.94 (br dd, J = 3.4, 13.6 Hz, 1H), 1.80–1.65 (m, 2H), 1.45–1.24 (m, 2H), 1.11 (t, J = 7.5 Hz, 3H), 0.88–0.74 (m, 2H), 0.69–0.61 (m, 1H), 0.59–0.50 (m, 1H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.76, 171.46, 158.48, 148.24, 143.89, 140.38, 134.14, 131.00, 125.61, 125.19, 108.55, 47.16, 34.04, 29.24, 28.68, 26.58, 12.41, 9.58, 8.24, 8.02. General Procedure for the Synthesis of Compounds 21­(a-k), 22, 23, 24, 25, 26a, 27a, 28a, and 33 General Procedure H: Suzuki-Miyaura Cross-Coupling BPin derivative (1.0 equiv), N-(4-bromothiazol-2-yl)­propionamide (1.2 equiv), K2CO3 (2.0 equiv), and PdCl2(dppf)-DCM (0.1 equiv) were dissolved under nitrogen in previously degassed 1,4-Dioxane (1.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C until starting material is consumed as indicated by LCMS. Water was added, and the reaction was extracted with EA. The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude product was dissolved in MeOH/DMSO and purified by preparative HPLC. N-(3-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­phenyl)­propionamide (21a). 20a (40 mg, 0.12 mmol, 1.0 equiv), N-(3-iodophenyl)­propionamide (50.4 mg, 0.18 mmol, 1.5 equiv), K2CO3 (33.8 mg, 0.24 mmol, 2.0 equiv), and PdCl2(dppf)–CH2Cl2 (9.98 mg, 0.012 mmol, 10 mol %) were dissolved under argon in previously degassed 1,4-dioxane (1 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 16 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 0.8 mL of MeOH added 0.2 mL of DMSO and purified by preparative HPLC. The fractions containing product were collected with DCM/MeOH (1/1), and the solvents were evaporated in vacuo to yield 33.6 mg (79%) of 21a. LCMS showed the desired product [M + H]+ = 349.2; UV = 99%, Rt = 1.24 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 9.94 (s, 1H), 8.00–7.90 (m, 1H), 7.57–7.50 (m, 2H), 7.48–7.42 (m, 2H), 7.41–7.34 (m, 1H), 7.34–7.27 (m, 1H), 3.76 (t, J = 6.4 Hz, 2H), 2.81 (t, J = 6.6 Hz, 2H), 2.35 (q, J = 7.5 Hz, 2H), 2.07–1.97 (m, 1H), 1.91 (quin, J = 6.5 Hz, 2H), 1.10 (t, J = 7.6 Hz, 3H), 0.98–0.91 (m, 2H), 0.87–0.79 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.66, 172.55, 140.54, 140.39, 138.70, 136.62, 133.12 (br s, 1C), 129.71, 127.03, 125.21, 124.46, 121.48, 118.31, 117.48, 43.69 (br d, J = 1.5 Hz, 1C), 30.03, 27.03, 24.10, 13.72, 10.11, 9.05. N-(5-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­pyridin-2-yl)­propionamide (21b). 20a (40 mg, 0,12 mmol, 1.0 equiv), N-(5-iodopyridin-2-yl)­propionamide (40.5 mg, 0.15 mmol, 1.2 equiv), K2CO3 (33.8 mg, 0.24 mmol, 2.0 equiv), and PdCl2(dppf)–CH2Cl2 (9.98 mg, 0.012 mmol, 10 mol %) were dissolved under argon in previously degassed 1,4-Dioxane (1.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 1 h. The solvent was removed under reduced pressure, and the crude was purified by preparative HPLC. The fractions containing the product were collected with DCM/MeOH (1/1), and the solvents were evaporated in vacuo to yield 29.3 mg (69%) of 21b as a white solid/foam. LCMS of the isolated product showed the desired product [M + H]+ = 350.2, UV= 99%, Rt = 1.11 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 10.52 (s, 1H), 8.64 (s, 1H), 8.20–8.14 (m, 1H), 8.12–8.04 (m, 1H), 7.59 (s, 1H), 7.57–7.47 (m, 2H), 3.76 (br t, J = 6.4 Hz, 2H), 2.80 (t, J = 6.4 Hz, 2H), 2.42 (q, J = 7.5 Hz, 2H), 2.05–1.96 (m, 1H), 1.91 (quin, J = 6.4 Hz, 2H), 1.09 (t, J = 7.5 Hz, 3H), 0.99–0.88 (m, 2H), 0.82 (br dd, J = 3.3, 7.3 Hz, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 173.39, 172.66, 151.72, 145.88, 138.74, 136.19, 133.36, 133.21, 130.77, 126.72, 125.29, 124.15, 113.62, 43.72, 29.79, 27.01, 24.07, 13.73, 9.94, 9.05. N-(5-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­pyridin-3-yl)­propionamide (21c). 20a (37.0 mg, 0.11 mmol, 1.0 equiv), N-(5-iodopyridin-3-yl)­propionamide (46.8 mg, 0.17 mmol, 1.5 equiv), K2CO3 (31.3 mg, 0.23 mmol, 2.0 equiv), and PdCl2(dppf)–CH2Cl2 (9.23 mg, 0.01 mmol, 0.1 equiv) were dissolved under argon in previously degassed 1,4-Dioxane (1 mL) and water (0.5 mL). The reaction stirred under heating to 80 °C for 1 h. The solvent was evaporated in vacuo. Water (10 mL) was added, and the residue was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over anhydrous Na2SO4, filtered off, and evaporated in vacuo. Purification by prep-HPLC afforded the titled compound 21c (25.4 mg, 64%) as a white solid. LCMS: 350.2 [M + H]+, UV= 97%, Rt = 0.92 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (DMSO-d 6, 400 MHz) δ 10.18 (s, 1H), 8.67 (d, 1H, J = 2.3 Hz), 8.7–8.7 (m, 1H), 8.56 (d, 1H, J = 2.0 Hz), 8.35 (t, 1H, J = 1.0 Hz), 7.5–7.6 (m, 1H), 7.53 (s, 1H), 7.5–7.5 (m, 1H), 3.77 (t, 2H, J = 1.0 Hz), 2.82 (t, 2H, J = 1.0 Hz), 2.39 (q, 2H, J = 1.0 Hz), 2.0–2.1 (m, 1H), 1.92 (quin, 2H, J = 1.0 Hz), 1.11 (t, 3H, J = 1.0 Hz), 0.9–1.0 (m, 2H), 0.8–0.9 (m, 2H); 13C NMR (DMSO-d 6, 101 MHz) δ 173.2, 172.7, 142.2, 139.7, 139.3, 136.5, 135.4, 133.3, 127.3, 125.4, 124.7, 123.9, 49.1, 43.8, 29.9, 27.0, 24.0, 13.8, 9.9, 9.1. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­pyridin-2-yl)­propionamide (21d). 20a (36.0 mg, 0.110 mmol, 1.0 equiv), N-(4-iodopyridin-2-yl)­propionamide (45.6 mg, 0.17 mmol, 1.5 equiv), K2CO3 (30.4 mg, 0.22 mmol, 3.0 equiv), and PdCl2(dppf)–CH2Cl2 (8.98 mg, 0.01 mmol, 0.1 equiv) were dissolved under argon in previously degassed 1,4-Dioxane (1 mL) and water (0.5 mL). The reaction stirred under heating to 80 °C for 1 h. The solvent was evaporated in vacuo. Water (10 mL) was added, and the residue was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over anhydrous Na2SO4, filtered off, and evaporated in vacuo. Purification by prep-HPLC afforded the titled compound 21d (20.2 mg, 53%) as a white solid. LCMS: 350.2 [M + H]+, UV= 100%, Rt = 1.02 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (DMSO-d 6, 400 MHz) δ 10.40 (s, 1H), 8.21 (s, 1H), 8.00 (s, 1H), 7.55 (d, 1H, J = 1.0 Hz), 7.3–7.3 (m, 1H), 7.2–7.3 (m, 1H), 3.79 (t, 2H, J = 1.0 Hz), 2.80 (t, 2H, J = 1.0 Hz), 2.39 (q, 2H, J = 1.0 Hz), 2.22 (s, 3H), 2.0–2.1 (m, 1H), 1.92 (quin, 2H, J = 1.0 Hz), 1.06 (t, 2H, J = 1.0 Hz), 1.0–1.1 (m, 1H), 0.9–1.0 (m, 2H), 0.8–0.9 (m, 2H); 13C NMR (DMSO-d 6, 101 MHz) δ 173.6, 172.8, 153.4, 149.0, 148.9, 140.2, 133.8, 127.2, 125.4, 124.7, 117.1, 110.7, 43.8, 29.8, 27.0, 24.0, 13.9, 9.9, 9.1. N-(6-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­pyrimidin-4-yl)­propionamide (21e). 20a (40 mg, 0.12 mmol, 1.0 equiv), N-(6-iodopyrimidin-4-yl)­propionamide (40.6 mg, 0.15 mmol, 1.2 equiv), K2CO3 (33.8 mg, 0.24 mmol, 2.0 equiv), and PdCl2(dppf)–CH2Cl2 (9.98 mg, 0.012 mmol, 10 mol %) were dissolved under argon in previously degassed 1,4-Dioxane (1.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 4 h. The solvent was removed under reduced pressure, and the crude was dissolved in 1.8 mL of MeCN/DMSO (3/1) and purified by preparative HPLC. The fractions containing the product were collected with DCM/MeOH (1/1), and the solvents were evaporated in vacuo to yield 29.5 mg (69%) of 21e as a white solid. LCMS of the isolated product showed desired product [M + H]+ = 351.2, UV= 100%, Rt = 1.15 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 10.92 (s, 1H), 8.90 (d, J = 1.3 Hz, 1H), 8.57 (d, J = 1.3 Hz, 1H), 7.94 (d, J = 2.0 Hz, 1H), 7.93–7.88 (m, 1H), 7.62 (d, J = 8.5 Hz, 1H), 3.79 (t, J = 6.4 Hz, 2H), 2.85 (t, J = 6.5 Hz, 2H), 2.50–2.44 (m, 2H), 2.06–1.98 (m, 1H), 1.92 (quin, J = 6.4 Hz, 2H), 1.09 (t, J = 7.4 Hz, 3H), 0.99–0.92 (m, 2H), 0.89–0.82 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 174.92, 172.97, 163.82, 159.24, 158.83, 141.67, 132.89, 132.56, 127.43, 125.11, 124.87, 104.55, 99.99, 43.98, 29.97, 27.09, 23.92, 13.97, 9.48, 9.24. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)-5-methylpyridin-2-yl)­propionamide (21f). 20a (37.0 mg, 0.11 mmol, 1.0 equiv), N-(4-iodo-5-methylpyridin-2- yl)­propionamide (49.2 mg, 0.17 mmol, 1.5 equiv), K2CO3 (31.3 mg, 0.23 mmol, 2.0 equiv), and PdCl2(dppf)–CH2Cl2 (9.23 mg, 0.01 mmol, 0.1 equiv) were dissolved under argon in previously degassed 1,4-Dioxane (1 mL) and water (0.5 mL). The reaction stirred under heating to 80 °C for 2 h. The solvent was evaporated in vacuo. Water (10 mL) was added, and the residue was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over anhydrous Na2SO4, filtered, and evaporated in vacuo. Purification by prep-HPLC afforded the titled compound 21f (20.2 mg, 53%) as a white solid. LCMS: 364.2 [M + H]+, UV = 97%, Rt = 1.06 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (DMSO-d 6, 400 MHz) δ 10.40 (s, 1H), 8.21 (s, 1H), 8.00 (s, 1H), 7.55 (d, 1H, J = 1.0 Hz), 7.3–7.3 (m, 1H), 7.2–7.3 (m, 1H), 3.79 (t, 2H, J = 1.0 Hz), 2.80 (t, 2H, J = 1.0 Hz), 2.39 (q, 2H, J = 1.0 Hz), 2.22 (s, 3H), 2.0–2.1 (m, 1H), 1.92 (quin, 2H, J = 1.0 Hz), 1.06 (t, 2H, J = 1.0 Hz), 1.0–1.1 (m, 1H), 0.9–1.0 (m, 2H), 0.8–0.9 (m, 2H); 13C NMR (DMSO-d 6, 101 MHz) δ 173.2, 172.8, 151.0, 150.1, 149.3, 139.0, 135.4, 132.8, 129.0, 126.4, 125.9, 124.7, 113.7, 43. N-(5-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)-1,3,4-thiadiazol-2-yl)­propionamide (21g). 20a (40 mg, 1.0 equiv, 0.12 mmol), N-(5-bromo-1,3,4-thiadiazol-2-yl)­propionamide (34.6 mg, 1.2 equiv, 0.15 mmol), K2CO3 (33.8 mg, 2.0 equiv, 0.24 mmol), and PdCl2(dppf)–CH2Cl2 (9.98 mg, 0.1 equiv, 0.012 mmol) were dissolved under nitrogen in previously degassed 1,4-Dioxane (1.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 4 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 1.8 mL of MeOH/DMSO (3/1) and purified by preparative HPLC. The fractions containing product were collected with DCM/MeOH (1/1), and the solvents were evaporated in vacuo to yield 21.4 mg (49%) of 21g as a pale brownish solid. LCMS of the isolated solid showed the desired product [M + H]+ = 357.4; UV = 100%, Rt = 1.12 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.57 (s, 1H), 7.80 (d, J = 2.0 Hz, 1H), 7.79–7.73 (m, 1H), 7.59 (d, J = 8.3 Hz, 1H), 3.78 (t, J = 6.4 Hz, 2H), 2.82 (t, J = 6.5 Hz, 2H), 2.08–1.96 (m, 1H), 1.91 (quin, J = 6.5 Hz, 2H), 1.12 (t, J = 7.5 Hz, 3H), 0.98–0.92 (m, 2H), 0.88–0.81 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.93, 172.74, 161.70, 158.60, 141.10, 133.43, 127.45, 126.42, 125.36, 124.87, 43.99, 28.73, 26.90, 23.86, 13.90, 9.50, 9.22. N-(3-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)-1H-pyrazol-5-yl)­propionamide (21h). 20a (40 mg, 0.12 mmol, 1.0 equiv), N-(5-bromo-1-propionyl-1H-pyrazol-3-yl)­propionamide (40.2 mg, 0.15 mmol, 1.2 equiv), K2CO3 (33.8 mg, 0.24 mmol, 2.0 equiv), and PdCl2(dppf)–CH2Cl2 (9.98 mg, 0.012 mmol, 10 mol %) were dissolved under argon in previously degassed 1,4-dioxane (1.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 6 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 1.3 mL of MeOH and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 28.0 mg (68%) of 21h as a white solid. LCMS of the isolated solid showed the desired product [M + H]+ = 339.2, 100% UV, Rt = 0.98 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.71 (br s, 1H), 10.32 (br s, 1H), 7.58 (s, 1H), 7.55–7.51 (m, 1H), 7.50–7.44 (m, 1H), 6.88 (br s, 1H), 3.75 (t, J = 6.4 Hz, 2H), 2.77 (t, J = 6.5 Hz, 2H), 2.31 (q, J = 7.6 Hz, 2H), 2.04–1.94 (m, 1H), 1.93–1.85 (m, 2H), 1.08 (t, J = 7.5 Hz, 3H), 0.96–0.89 (m, 2H), 0.88–0.78 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.68, 171.62, 148.84, 141.80, 138.90, 133.16, 125.94, 125.52, 125.14, 122.87, 93.91, 43.74, 29.18, 26.96, 24.02, 13.73, 10.19, 9.06. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiophen-2-yl)­propionamide (21i). 20a (40 mg, 0.12 mmol, 1.0 equiv), N-(4-bromothiophen-2-yl)­propionamide (34.3 mg, 0.15 mmol, 1.2 equiv), K2CO3 (33.8 mg, 0.24 mmol, 2.0 equiv), and PdCl2(dppf)–CH2Cl2 (9.98 mg, 0.012 mmol, 10 mol %) were dissolved under argon in previously degassed 1,4-Dioxane (1 mL) and Water (0.5 mL). The reaction was stirring under heating to 80 °C for 2 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 1.0 mL MeOH and 0.3 mL ACN, then it was purified by preparative HPLC and repurified by SFC delivering 23.2 mg (54%) of 21i as a white foam. LCMS of the isolated solid showed the desired product at Rt = 1.23 min: [M + H]+ = 355.2/[M + H]− = 353.1 with a 97% purity by UV (Acquity UPLC BEH C18; 5–100%, Acid, 2 min). 1H NMR (400 MHz, DMSO-d 6) δ = 11.15 (s, 1H), 7.51–7.39 (m, 3H), 7.20 (d, J = 1.5 Hz, 1H), 6.97 (d, J = 1.5 Hz, 1H), 3.74 (t, J = 6.5 Hz, 2H), 2.77 (t, J = 6.6 Hz, 2H), 2.37 (q, J = 7.7 Hz, 2H), 2.05–1.95 (m, 1H), 1.89 (quin, J = 6.5 Hz, 2H), 1.11 (t, J = 7.5 Hz, 3H), 0.95–0.89 (m, 2H), 0.85–0.77 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.57, 170.74, 141.16, 138.03, 137.56, 133.11, 132.09, 126.10, 125.08, 123.65, 111.92, 109.12, 43.63, 28.84, 26.98, 24.11, 13.69, 10.01, 9.01. N-(4-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)-5-methylthiazol-2-yl)­propionamide (21j). 20a (40.0 mg, 1.0 equiv, 0.12 mmol), N-(4-bromo-5-methylthiazol-2-yl)­propionamide (36.5 mg, 1.2 equiv, 0.15 mmol), K2CO3 (33.8 mg, 2.0 equiv, 0.24 mmol), and PdCl2(dppf)–CH2Cl2 (9.98 mg, 0.1 equiv, 0.012 mmol) were dissolved under nitrogen in previously degassed 1,4-Dioxane (1.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 1 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 1.5 mL of MeOH/DMSO (3:1) and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 22.6 mg (50%) of 21j as a pale brownish solid. LCMS of the isolated solid showed the desired product [M + H]+ = 370.4, 100% UV, Rt = 1.26 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.01 (s, 1H), 7.71–7.28 (m, 3H), 3.76 (t, J = 6.4 Hz, 2H), 2.78 (t, J = 6.5 Hz, 2H), 2.48 (s, 3H), 2.43 (q, J = 7.5 Hz, 2H), 2.09–1.96 (m, 1H), 1.90 (quin, J = 6.5 Hz, 2H), 1.10 (t, J = 7.6 Hz, 3H), 0.95–0.88 (m, 2H), 0.86–0.78 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.65, 172.40, 154.32, 143.86, 138.12, 132.39, 131.54, 128.50, 125.75, 124.59, 120.76, 43.69, 28.64, 27.01, 24.11, 13.69, 12.39, 9.66, 9.04. N-(5-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)-1-methyl-1H-pyrazol-3-yl)­propionamide (21k). 20a (50 mg, 0.15 mmol, 1.0 equiv), N-(5-bromo-1-methyl-1H-pyrazol-3-yl)­propionamide (42.6 mg, 0.18 mmol, 1.2 equiv), K2CO3 (42.2 mg, 0.31 mmol, 2.0 equiv), and PdCl2(dppf)–CH2Cl2 (12.5 mg, 0.015 mmol, 10 mol %) were dissolved under argon in previously degassed 1,4-Dioxane (1.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 1 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 1.3 mL of MeOH and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 38.0 mg (70%) of 21k as a white solid. LCMS of the isolated solid showed the desired product [M + H]+ = 353.2, 100% UV, Rt = 1.04 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 10.34 (s, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.38 (d, J = 1.8 Hz, 1H), 7.35 (dd, J = 2.3, 8.3 Hz, 1H), 6.61 (s, 1H), 3.80–3.72 (m, 5H), 2.80 (t, J = 6.6 Hz, 2H), 2.29 (q, J = 7.7 Hz, 2H), 2.07–1.95 (m, 1H), 1.91 (quin, J = 6.5 Hz, 2H), 1.06 (t, J = 7.6 Hz, 3H), 0.96–0.90 (m, 2H), 0.87–0.80 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ 165.74, 165.71, 155.07, 152.63, 144.94, 144.87, 126.88, 122.07, 121.99, 119.12, 119.08, 117.05, 116.82, 66.15, 52.44, 50.24, 50.20, 38.49, 29.02, 21.89. N-(4-(1-(2-chloroacetyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­propionamide (22). 20b (40.0 mg, 1.0 equiv, 0.12 mmol), N-(4-bromothiazol-2-yl)­propionamide (56.0 mg, 1.2 equiv, 0.14 mmol), K2CO3 (32.9 mg, 2.0 equiv, 0.24 mmol), and PdCl2(dppf)–CH2Cl2 (9.7 mg, 0.1 equiv, 0.012 mmol) were dissolved under nitrogen in previously degassed 1,4-Dioxane (1.0 mL) and Water (0.5 mL). The reaction was stirring under heating to 80 °C for 2 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 1.8 mL of MeOH/DMSO (4/1) and purified by preparative HPLC. The fractions containing product were collected and the solvents evaporated in vacuo to yield 7.9 mg (18%) of 22 as a pale yellow solid. LCMS of the isolated solid showed the desired mass, [M + H]+ = 364.3, 100% UV, Rt = 1.20 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.18 (br s, 1H), 7.72 (s, 1H), 7.69 (br d, J = 8.4 Hz, 1H), 7.61 (br dd, J = 3.4, 7.3 Hz, 1H), 7.55 (s, 1H), 4.55 (s, 2H), 3.72 (t, J = 6.3 Hz, 2H), 2.77 (t, J = 6.6 Hz, 2H), 2.45 (q, J = 7.5 Hz, 2H), 1.92 (quin, J = 6.4 Hz, 2H), 1.09 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.26, 165.50, 157.94, 148.20, 137.35, 125.87, 124.11, 123.21, 107.47, 43.36, 28.23, 26.38, 23.22, 9.15. N-(4-(1-Acryloyl-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­propionamide (23). 20c (40.0 mg, 1.0 equiv, 0.13 mmol), N-(4-bromothiazol-2-yl)­propionamide (60.1 mg, 1.2 equiv, 0.15 mmol), K2CO3 (35.3 mg, 2.0 equiv, 0.26 mmol), and PdCl2(dppf)–CH2Cl2 (10.4 mg, 0.1 equiv, 0.013 mmol) were dissolved under nitrogen in previously degassed 1,4-Dioxane (1.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 2 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 1 mL MeOH/DMSO 0.5 mL and purified by preparative HPLC. The fractions containing the product were collected and the solvents evaporated in vacuo to yield 21 mg (48%) of 23 as a pale yellow solid. LCMS of the isolated solid showed the desired product at Rt = 1.17 min with a 100% purity by UV (Acquity UPLC BEH C18; 5–100%, Acid, 2 min) [M + H]+ = 342.3/[M + H]− = 340.3; 1H NMR (400 MHz, DMSO-d 6) δ = 12.18 (br s, 1H), 7.74 (d, J = 1.9 Hz, 1H), 7.69 (dd, J = 2.1, 8.3 Hz, 1H), 7.54 (s, 1H), 7.18 (br d, J = 7.6 Hz, 1H), 6.59 (dd, J = 10.3, 16.8 Hz, 1H), 6.23 (dd, J = 2.3, 16.8 Hz, 1H), 5.79–5.67 (m, 1H), 3.75 (t, J = 6.4 Hz, 2H), 2.75 (t, J = 6.5 Hz, 2H), 2.45 (q, J = 7.6 Hz, 2H), 1.90 (quin, J = 6.5 Hz, 2H), 1.09 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.25, 164.61, 157.95, 148.21, 137.39, 130.89, 130.12, 127.48, 125.73, 124.68, 123.20, 107.36, 43.30, 28.23, 26.52, 23.79–23.53, 9.14. N-(4-(1-(But-3-enoyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­propionamide (24). 20d (20 mg, 1.0 equiv, 0.061 mmol), N-(4-bromothiazol-2-yl)­propionamide (21.6 mg, 1.5 equiv, 0.091 mmol), K2CO3 (16.9 mg, 2.0 equiv, 0.12 mmol), and PdCl2(dppf)·DCM (4.99 mg, 0.1 equiv, 0.06 mmol) were dissolved under nitrogen in previously degassed 1,4-Dioxane (1.0 mL) and Water (0.5 mL). The reaction was stirring under heating to 80 °C for 2 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. Crude was purified by preparative HPLC to yield 6.7 mg of 24 (31%) as a colorless sticky oil. LCMS of the product showed the desired product [M + H]+ = 356.2, 100% purity by UV, Rt = 2.08 min (Xbridge 10–100 Basic, 3 min). 1H NMR (400 MHz, DMSO-d6) δ = 12.19 (s, 1H), 7.79–7.62 (m, 2H), 7.61–7.43 (m, 2H), 6.01–5.82 (m, 1H), 5.24–4.90 (m, 2H), 3.80–3.61 (m, 2H), 3.35 (br d, J = 6.8 Hz, 2H), 2.76 (t, J = 6.6 Hz, 2H), 2.46 (q, J = 7.5 Hz, 2H), 1.96–1.86 (m, 2H), 1.11 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ = 172.71, 170.30, 158.40, 148.78, 141.47, 138.23, 133.18, 126.22, 125.09, 123.49, 117.81, 107.73, 28.70, 27.01, 26.98, 24.04, 23.97, 9.62. N-(4-(1-(2-(Oxiran-2-yl)­acetyl)-1,2,3,4-tetrahydroquinolin-6-yl)­thiazol-2-yl)­propionamide (25). 20e (170 mg, 1.0 equiv, 0.5 mmol), N-(4-bromothiazol-2-yl)­propionamide (174.7 mg, 1.5 equiv, 0.74 mmol), K2CO3 (136.9 mg, 2.0 equiv, 0.99 mmol), and PdCl2(dppf)·DCM (40.4 mg, 0.1 equiv, 0.049 mmol) were dissolved under nitrogen in previously degassed 1,4-Dioxane (3.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 18 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. Crude was dissolved in MeOH/acetone, and it was purified by preparative HPLC. The fractions containing product were collected, and the solvents were evaporated in vacuo to yield 7 mg of product 25 (4%) as a colorless sticky oil. LCMS showed product, UV = 98%, Rt = 1.89 min, [M + H]+ = 372.3/[M + H]−=370.2 (XBridge C18 3.5 μm; 4.6 × 50 mm at 40 °C; 10–100% (Water 5 mM ammonium bicarbonate/Acetonitrile), 3 min at 1 mL/min). 1H NMR (400 MHz, DMSO-d6) δ = 12.17 (br s, 1H), 7.72 (s, 1H), 7.68 (dd, J = 2.0, 8.3 Hz, 1H), 7.64–7.43 (m, 2H), 3.81–3.61 (m, 2H), 3.30–3.23 (m, 1H), 2.91–2.82 (m, 1H), 2.82–2.65 (m, 4H), 2.46 (q, J = 7.6 Hz, 2H), 1.99–1.84 (m, 2H), 1.11 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ = 172.71, 169.83, 158.38, 148.76, 138.24, 126.19, 125.14, 123.52, 107.72, 49.24, 46.25, 38.35, 28.70, 26.99, 23.92, 9.61. N-(4-(4-(Cyclopropanecarbonyl)-3,4-dihydro-2H-benzo­[b]­[1,4]­oxazin-7-yl)­thiazol-2-yl)­propionamide (26a). 31a (40.0 mg, 1.0 equiv, 0.12 mmol), N-(4-bromothiazol-2-yl)­propionamide (57.1 mg, 1.2 equiv, 0.15 mmol), K2CO3 (33.6 mg, 2.0 equiv, 0.24 mmol), and PdCl2(dppf)–CH2Cl2 (9.9 mg, 0.1 equiv, 0.012 mmol) were dissolved under nitrogen in previously degassed 1,4-dioxane (1.0 mL) and water (0.5 mL). The reaction was stirring under heating to 80 °C for 1 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 1.5 mL of MeOH/DMSO 4:1 and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 25.0 mg (57%) of 26a as a pale-yellow solid. LCMS of the isolated solid showed the desired mass, [M + H]+ = 358.3, 100% UV, Rt = 1.20 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.17 (s, 1H), 7.74–7.60 (m, 1H), 7.57 (s, 1H), 7.51–7.37 (m, 2H), 4.36–4.26 (m, 2H), 3.98 (br s, 2H), 2.47 (q, J = 7.5 Hz, 2H), 2.20–2.06 (m, 1H), 1.11 (t, J = 7.5 Hz, 3H), 0.95 (dd, J = 2.6, 4.9 Hz, 2H), 0.92–0.86 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.74, 171.75, 158.36, 148.41, 146.82, 132.00, 126.20, 124.47, 117.78, 114.31, 108.09, 66.77, 28.68, 13.39, 9.60, 9.06. N-(4-(4-(Cyclopropanecarbonyl)-3,4-dihydro-2H-benzo­[b]­[1,4]­thiazin-7-yl)­thiazol-2-yl)­propionamide (27a). 31b (40.0 mg, 1.0 equiv, 0.12 mmol), N-(4-bromothiazol-2-yl)­propionamide (32.7 mg, 1.2 equiv, 0.14 mmol), K2CO3 (32.0 mg, 2.0 equiv, 0.23 mmol), and PdCl2(dppf)–CH2Cl2 (9.5 mg, 0.1 equiv, 0.012 mmol) were dissolved under nitrogen in previously degassed 1,4-dioxane (1.0 mL) and water (0.5 mL). The reaction was stirred under heating to 80 °C for 3 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. The crude was dissolved in 1.0 mL of MeOH and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 20.0 mg (45%) of 27a as a white solid. LCMS of the isolated product showed the desired mass, [M + H]+ = 374.3, 100% UV, Rt = 1.26 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6DMSO-d 6) δ = 12.17 (s, 1H), 7.80 (d, J = 1.9 Hz, 1H), 7.71–7.57 (m, 2H), 7.40 (d, J = 8.4 Hz, 1H), 3.94 (br s, 2H), 3.20 (t, J = 5.6 Hz, 2H), 2.48–2.41 (m, 2H), 1.91 (td, J = 3.7, 7.6 Hz, 1H), 1.09 (t, J = 7.6 Hz, 3H), 0.96–0.88 (m, 2H), 0.85–0.76 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.29, 171.68, 158.01, 147.44, 136.80, 132.05, 128.66, 126.84, 123.89, 121.71, 108.22, 28.35, 28.22, 12.61, 9.11, 8.82. N-(4-(1-(Cyclopropanecarbonyl)-2,3,4,5-tetrahydro-1H-benzo­[b]­azepin-7-yl)­thiazol-2-yl)­propionamide (28a). 31c (40.0 mg, 1.0 equiv, 0.12 mmol), N-(4-bromothiazol-2-yl)­propionamide (55.1 mg, 1.2 equiv, 0.14 mmol), K2CO3 (32.4 mg, 2.0 equiv, 0.23 mmol), and PdCl2(dppf)–CH2Cl2 (9.6 mg, 0.1 equiv, 0.012 mmol) were dissolved under nitrogen in previously degassed 1,4-dioxane (1.0 mL) and water (0.5 mL). The reaction was stirred under heating to 80 °C for 1 h. Water was added, and the reaction was extracted with EA (3 × 10 mL). The organic layer was dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure. The crude was dissolved in 1.8 mL of MeOH/DMSO (3/1) and purified by preparative HPLC. The fractions containing product were collected with DCM/MeOH (1/1), and the solvents were evaporated in vacuo to yield 19.0 mg (43%) of 28a as a pale yellow solid. LCMS of the isolated solid showed the desired product [M + H]+ = 370.3; UV= 98%, Rt = 1.28 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min), 3 min at 1 mL/min); 1H NMR (400 MHz, DMSO-d 6) δ = 12.21 (s, 1H), 7.88 (d, J = 2.0 Hz, 1H), 7.79 (dd, J = 2.0, 8.0 Hz, 1H), 7.63 (s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 4.62–4.49 (m, 1H), 2.87–2.66 (m, 2H), 2.65–2.54 (m, 1H), 2.50–2.42 (m, 2H), 1.96 (br dd, J = 3.1, 13.6 Hz, 1H), 1.80–1.66 (m, 2H), 1.45–1.32 (m, 2H), 1.11 (t, J = 7.5 Hz, 3H), 0.80 (t, J = 3.9 Hz, 2H), 0.73–0.50 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 172.78, 171.47, 158.49, 148.51, 142.82, 141.13, 134.07, 128.84, 127.77, 124.90, 108.69, 47.12, 34.58, 29.26, 28.69, 26.55, 12.57, 9.60, 8.14. tert -Butyl (1-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­pyrrolidin-3-yl)­carbamate (33). 30d (100.0 mg, 1.0 equiv, 0.37 mmol), tert-butyl pyrrolidin-3-ylcarbamate (199.45 mg, 3.0 equiv, 1.07 mmol), Tris­(dibezylideneacetone)­dipalladium (32.7 mg, 0.10 equiv, 0.036 mmol), sodium tert-butoxide (34.3 mg, 1.0 equiv, 0.36 mmol), and 2′-Dicyclohexylphosphino-2-(N,N-dimethylamino)­biphenyl (16.8 mg, 0.12 equiv, 0.042 mmol) were placed under nitrogen in a microwave vial. Previously degassed 1,4-Dioxane (6.0 mL) was added, and the reaction was stirred under heating to 90 °C for 18 h. The solvent was removed under reduced pressure, and the crude was purified by column chromatography on silica gel (Ilok 12 g, 16 CV) eluting with CH/EA 0–10–30%. The column delivered 150.3 mg (100%) of product 33 as a pale yellow solid. LCMS m/z, [M + H]+ 386.3; 1H NMR (400 MHz, DMSO-d 6) δ = 7.18 (br d, J = 6.5 Hz, 2H), 6.44–6.31 (m, 2H), 4.20–4.03 (m, 1H), 3.73–3.54 (m, 2H), 3.44 (dd, J = 6.5, 9.5 Hz, 1H), 3.26–3.14 (m, 1H), 3.02 (dd, J = 5.0, 9.5 Hz, 1H), 2.62 (t, J = 6.5 Hz, 2H), 2.20–2.07 (m, 1H), 1.96–1.75 (m, 4H), 1.51–1.30 (m, 11H), 0.91–0.82 (m, 2H), 0.77–0.67 (m, 2H). N-(1-(1-(Cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-6-yl)­pyrrolidin-3-yl)­propionamide (34). 33 (150 mg, 1.0 equiv, 0.39 mmol) was dissolved in dry methanol (2.0 mL) and placed at 0 °C. HCl (2.0 mL, 4.0 M, 20.6 equiv, 8.0 mmol) in dioxane was slowly added, and the reaction mixture was stirred and allowed to warm up to room temperature for 2 h. The solvent was removed under reduced pressure delivering 150 mg (98%) of a pale yellow solid. The crude showed the deprotected product and was used in the next step without further purification. LCMS m/z [M + H]+ 286.3; 1H NMR (400 MHz, DMSO-d 6) δ = 8.33 (br s, 2H), 7.26–7.16 (m, 1H), 6.49–6.37 (m, 2H), 3.98–3.87 (m, 1H), 3.71–3.59 (m, 2H), 3.53–3.44 (m, 2H), 3.36–3.24 (m, 2H), 2.65 (t, J = 6.6 Hz, 2H), 2.37–2.26 (m, 1H), 2.17–2.01 (m, 1H), 1.94–1.78 (m, 3H), 0.90–0.82 (m, 2H), 0.74 (td, J = 3.2, 7.7 Hz, 2H). The crude product from the previous reaction (150.0 mg, 1.0 equiv, 0.47 mmol) was dissolved in anhydrous DCM (5.0 mL) and treated with triethylamine (94.3 mg, 0.13 mL, 2.0 equiv, 0.93 mmol). The reaction was placed at 0 °C and propionyl chloride (64.7 mg, 0.06 mL, 1.5 equiv, 0.70 mmol) was slowly added. The reaction mixture was stirred and allowed to warm up to room temperature for 1 h. The solvent was removed under reduced pressure; the crude was dissolved in 1.0 mL of MeOH and purified by preparative HPLC. The fractions containing product were collected and the solvents evaporated in vacuo to yield 54.3 mg (34%) of 34 as a pale brownish solid. LCMS of the isolated solid showed the desired product [M + H]+ = 342.4, 100% UV, Rt = 1.06 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 8.04 (d, J = 7.0 Hz, 1H), 7.29–7.07 (m, 1H), 6.39 (br d, J = 6.3 Hz, 2H), 4.43–4.28 (m, 1H), 3.64 (br s, 2H), 3.46 (dd, J = 6.4, 9.6 Hz, 1H), 3.36–3.34 (m, 1H), 3.29–3.19 (m, 1H), 3.03 (dd, J = 4.4, 9.6 Hz, 1H), 2.63 (t, J = 6.6 Hz, 2H), 2.22–2.12 (m, 1H), 2.08 (q, J = 7.7 Hz, 2H), 1.96–1.76 (m, 4H), 0.99 (t, J = 7.6 Hz, 3H), 0.89–0.82 (m, 2H), 0.76–0.69 (m, 2H); 13C NMR (101 MHz, DMSO-d 6) δ = 173.26, 171.97, 145.54, 128.11, 125.62, 111.29, 109.67, 53.84, 49.03, 46.32, 31.37, 28.78, 27.12, 24.37, 13.14, 10.34, 8.55. N -Methyl-6-(4-(morpholinomethyl)­piperidin-1-yl)­picolinamide (41a). In a two-armed round-bottomed flask (25 mL), to a stirred solution of 39a (100.0 mg, 0.36 mmol, 1.0 equiv) in dry 1,4-Dioxane (4 mL), cesium carbonate (355.0 mg, 1.1 mmol, 3.0 equiv) followed by 6-chloro-N-methylpicolinamide 40 (62.0 mg, 0.36 mmol, 1.0 equiv) were added. Nitrogen was flashed into the white suspension using a balloon for 30 min and then palladium­(II) acetate (3.3 mg, 0.015 mmol, 0.04 equiv) and BINAP (15.8 mg, 0.025 mmol, 0.07 equiv) were added. The reaction mixture was stirred at 100 °C for 16 h. The resulting reaction mixture (yellow suspension) was filtered through Celite and evaporated under vacuum. Water (5 mL) was added, and the mixture was extracted with EtOAc (3 × 5 mL). The combined organic layers were washed with brine (1 × 5 mL), dried over anhydrous Na2SO4 and evaporated in vacuo. The resulting crude product was purified by prep-HPLC to afford the titled compound 41a (2.6 mg, 3%) as a brown oil. LCMS: 319 [M + H]+, UV = 95%, Rt = 0.58 min (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (Methanol-d4, 400 MHz) δ 7.6–7.7 (m, 1H), 7.3–7.3 (m, 1H), 7.0–7.0 (m, 1H), 4.4–4.5 (m, 2H), 3.7–3.7 (m, 3H), 2.97 (s, 3H), 2.8–2.9 (m, 2H), 2.48 (br s, 4H), 2.26 (d, 2H, J = 6.8 Hz), 1.9–1.9 (m, 1H), 1.8–1.9 (m, 2H), 1.2–1.4 (m, 3H); 13C NMR (Methanol-d4, 101 MHz) δ 166.9, 158.3, 147.4, 138.2, 110.1, 66.4, 64.9, 53.9, 45.0, 33.0, 30.2, 25.0. N -Methyl-6-(4-(2-morpholinoethyl)­phenyl)­picolinamide (41b). 42 (50 mg, 1.0 equiv, 0.16 mmol), 40 (53.7 mg, 1.3 equiv, 0.20 mmol), K2CO3 (43.6 mg, 2.0 equiv, 0.32 mmol), and PdCl2(dppf)·DCM (12.9 mg, 0.1 equiv, 0.16 mmol) were dissolved under nitrogen in previously degassed 1,4-Dioxane (1.0 mL) and water (0.5 mL). The reaction was stirred and heated at 80 °C for 1 h. The reaction mixture was treated with water (10 mL) and extracted with EA (3 × 20 mL), washed with brine (10 mL), and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and the crude was dissolved in 1.5 mL of MeOH/DMSO 4:1 and purified by preparative HPLC-MS. The fractions containing product were collected with DCM and the solvents were evaporated in vacuo to yield 40.4 mg of 41b (79%) as a white solid. LCMS of the isolated product showed desired product [M + H]+ = 326.3; UV = 100%, Rt = 1.79 min (XBridge C18 3.5 μm; 4.6 × 50 mm at 40 °C; 10–100% (Water 5 mM ammonium bicarbonate/Acetonitrile), 3 min at 1 mL/min). 1H NMR (400 MHz, DMSO-d 6) δ = 8.85 (br d, J = 4.8 Hz, 1H), 8.25–8.20 (m, 2H), 8.17–8.10 (m, 1H), 8.03 (t, J = 7.8 Hz, 1H), 7.97–7.90 (m, 1H), 7.38 (d, J = 8.3 Hz, 2H), 3.64–3.52 (m, 4H), 2.89 (d, J = 5.0 Hz, 3H), 2.86–2.79 (m, 2H), 2.60–2.54 (m, 2H), 2.48–2.40 (m, 4H); 13C NMR (101 MHz, DMSO-d 6) δ = 164.87, 155.39, 150.34, 142.61, 139.12, 135.77, 129.52, 127.39, 122.63, 120.46, 66.68, 60.28, 53.73, 32.62, 26.54. 2-Methyl-5-(piperidin-4-yl)­quinoline, Hydrochloride (46c). Step 1. tert -Butyl 4-(2-methylquinolin-5-yl)-3,6-dihydropyridine-1­(2H)-carboxylate. 43 (500 mg, 1.0 equiv, 2.25 mmol), 44 (835.4 mg, 1.2 equiv, 2.7 mmol), K2CO3 (622.3 mg, 2.0 equiv, 4.5 mmol) and PdCl2(dppf)–CH2Cl2 (183.9 mg, 0.1 equiv, 0.23 mmol) were dissolved under nitrogen in previously degassed 1,4-dioxane (4.0 mL) and water (2.0 mL). The reaction was stirred under heating to 80 °C for 2 h. The reaction mixture was treated with water (10 mL) and extracted with EA (3 × 20 mL), washed with brine (10 mL), and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and the crude was purified by column chromatography on silica gel eluting with CH to CH/EtOAc 0–30–50% (column IloK 40 g, 24 CV) delivering 750 mg of the desired coupled product (95%) isolated as a dark brownish sticky oil. LCMS [M + H]+ 325, UV 93%; 1H NMR (400 MHz, DMSO-d 6) δ = 8.26 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.67 (dd, J = 7.1, 8.4 Hz, 1H), 7.41 (d, J = 8.5 Hz, 1H), 7.36 (dd, J = 1.0, 7.0 Hz, 1H), 5.76 (s, 1H), 4.06 (br d, J = 2.0 Hz, 2H), 3.65 (t, J = 5.6 Hz, 2H), 2.66 (s, 3H), 2.47–2.38 (m, 2H), 1.46 (s, 9H). Step 2. tert -Butyl 4-(2-methylquinolin-5-yl)­piperidine-1-carboxylate. The isolated product (750 mg, 1.0 equiv, 2.3 mmol) was dissolved under nitrogen in Ethanol (10 mL). Pd/C (246 mg, 10 wt %, 0.1 equiv, 0.23 mmol) was added and the reaction was hydrogenated at 40 psi in a Parr hydrogenator for 3 days. Crude was filtered through Celite and washed with ethanol (50 mL). The solvent was removed under reduced pressure, and the crude was purified by column chromatography on silica gel eluting with CH–CH/EA 100% (column IloK 40 g, 32 CV) delivering 108.9 mg (14%) of the desired reduced product. LCMS [M + H]+ 327, UV 100%; 1H NMR (400 MHz, DMSO-d 6) δ = 8.54 (d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.65 (dd, J = 7.4, 8.4 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.42 (d, J = 6.3 Hz, 1H), 4.13 (br d, J = 12.3 Hz, 2H), 3.61–3.46 (m, 1H), 3.16–2.87 (m, 2H), 2.66 (s, 3H), 1.83 (br d, J = 13.0 Hz, 2H), 1.61 (dq, J = 4.1, 12.5 Hz, 2H), 1.44 (s, 10H). Step 3. 2-Methyl-5-(piperidin-4-yl)­quinoline, Hydrochloride (46c). The previously reduced product (110.00 mg, 1.0 equiv, 0.34 mmol) was dissolved under nitrogen in methanol (3.0 mL) and placed at 0 °C. HCl (2.0 mL, 4.0 M) in 1,4-dioxane (2.0 mL) was added and the reaction mixture was stirred for 4 h and allowed to warm up to room temperature. The solvent was removed under reduced pressure delivering 95 mg of 46c (100%) used in the next step without further purification. LCMS [M + H]+ 227, UV 100%; 1H NMR (400 MHz, DMSO-d 6) δ = 9.35–9.19 (m, 1H), 9.16–8.89 (m, 2H), 8.24 (br d, J = 8.3 Hz, 1H), 8.05 (br t, J = 7.9 Hz, 1H), 7.95 (br d, J = 8.5 Hz, 1H), 7.70 (br d, J = 7.3 Hz, 1H), 3.91–3.75 (m, 1H), 3.26–3.08 (m, 4H), 2.96 (s, 3H), 2.10–1.91 (m, 4H). 5-(1-(3-Bromophenethyl)­piperidin-4-yl)-2-methylquinoline (47c). 3-Bromo-benzeneacetaldehyde 45 (113.6 mg, 1.5 equiv, 0.57 mmol) and 46c (100 mg, 1.0 equiv, 0.38 mmol) were dissolved under nitrogen in 1,2-dichloroethane (10 mL). Acetic acid (0.2 mL) was added and the reaction was stirred for 1 h. Sodium triacetoxyborohydride (120.98 mg, 1.5 equiv, 0.57 mmol) was added and the reaction was stirred at room temperature for another 16 h. The solvent was removed under reduced pressure and the crude was purified by column chromatography on silica gel eluting with CH to CH/EtOAc 0–20% (column IloK 12 g, 24 CV) delivering 82.7 mg of product 47c (53%) as a colorless sticky oil. LCMS [M + H]+ 409, UV 99%; 1H NMR (400 MHz, DMSO-d6) δ = 8.49 (d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.65 (dd, J = 7.3, 8.5 Hz, 1H), 7.52–7.48 (m, 1H), 7.44 (d, J = 8.8 Hz, 2H), 7.42–7.36 (m, 1H), 7.31–7.23 (m, 2H), 3.28 (br s, 1H), 3.09 (br d, J = 11.5 Hz, 2H), 2.84–2.75 (m, 2H), 2.65 (s, 3H), 2.63–2.55 (m, 2H), 2.26 (dt, J = 2.6, 11.4 Hz, 2H), 1.88–1.70 (m, 4H). 5-(4-(3-Bromophenethyl)­piperazin-1-yl)-2-methylquinoline (47a). 3-Bromo-benzeneacetaldehyde 45 (105.08 mg, 1.2 equiv, 0.53 mmol) and 2-Methyl-5-piperazin-1-yl-quinoline (46a, 100.0 mg, 1.0 equiv, 0.44 mmol) were dissolved under nitrogen in 1,2-dichloroethane (3.0 mL). Acetic acid (2.5 μL) was added and the reaction was stirred for 1 h. Sodium triacetoxyborohydride (139.86 mg, 1.5 equiv, 0.66 mmol) was added and the reaction was stirred at room temperature for another 1 h. The solvent was removed under reduced pressure and the crude was purified by column chromatography on silica gel eluting with CH to CH/EtOAc 0–60% (column IloK 12 g, 24 CV) delivering 188.4 mg (100%) of product 47a as a yellow sticky oil. LCMS [M + H]+ 410; UV 97%; 1H NMR (400 MHz, DMSO-d 6) δ = 8.33 (d, J = 8.6 Hz, 1H), 7.63–7.55 (m, 2H), 7.51–7.48 (m, 1H), 7.42–7.35 (m, 2H), 7.29 (s, 2H), 7.10 (dd, J = 2.6, 5.9 Hz, 1H), 3.02 (br s, 4H), 2.87–2.78 (m, 2H), 2.77–2.67 (m, 4H), 2.66–2.59 (m, 5H). 2-Methyl-5-(4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)­phenethyl)­piperazin-1-yl)­quinoline (49a). 47a (180 mg, 1.0 equiv, 0.44 mmol), B2Pin2 (133.7 mg, 1.2 equiv, 0.53 mmol), potassium acetate (86.10 mg, 2.0 equiv, 0.88 mmol), and PdCl2(dppf)–CH2Cl2 (17.9 mg, 0.05 equiv, 0.022 mmol) were dissolved in anhydrous previously degassed 1,4-Dioxane (3.0 mL). The reaction mixture was placed at 80 °C and stirred overnight for 1 h. The reaction mixture was treated with water (10 mL), extracted with EA (3 × 20 mL), washed with brine (10 mL), and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure, and the crude was purified by column chromatography on silica gel eluting with CH to CH/EtOAc 0–80% (column IloK 12 g, 24 CV) delivering 210 mg (75%) of product 49a isolated as a yellow sticky oil. LCMS [M + H]+ 458; 1H NMR (400 MHz, DMSO-d 6) δ = 8.33 (d, J = 8.6 Hz, 1H), 7.92 (s, 2H), 7.62–7.52 (m, 3H), 7.50 (d, J = 7.3 Hz, 1H), 7.42–7.35 (m, 2H), 7.33–7.27 (m, 1H), 7.10 (dd, J = 2.6, 6.1 Hz, 1H), 3.03 (br s, 4H), 2.85–2.79 (m, 2H), 2.74 (br s, 4H), 2.66–2.57 (m, 5H), 1.29 (s, 12H). (3-((4-(2-Methylquinolin-5-yl)­piperazin-1-yl)­methyl)­phenyl)­boronic acid (49b). 2-Methyl-5-piperazin-1-yl-quinoline (60 mg, 1.0 equiv, 0.26 mmol) and (3-formylphenyl)­boronic acid (47.5 mg, 1.2 equiv, 0.32 mmol) were dissolved under argon in 1,2-dichloroethane (3.0 mL). Acetic acid (10 μL) was added, and the reaction mixture was stirred at room temperature for 30 min. Sodium triacetoxyborohydride (83.9 mg, 1.5 equiv, 0.39 mmol) was added and the reaction mixture continued stirring for 4 h. Reaction mixture was treated with water (10 mL) and extracted with DCM (3 × 10 mL), dried over anhydrous Na2SO4 and filtered. The solvent was removed under reduced pressure and purified by column chromatography on silica gel eluting with CH/EA 0–80% (column IloK 12 g, 24 CV) delivering 68.6 mg (72%) of product 49b. LCMS [M + H]+ 362, UV 100%; 1H NMR (400 MHz, DMSO-d6) δ = 8.34 (d, J = 8.5 Hz, 1H), 8.04 (s, 2H), 7.77 (s, 1H), 7.70 (d, J = 7.3 Hz, 1H), 7.62–7.55 (m, 2H), 7.44–7.35 (m, 2H), 7.34–7.27 (m, 1H), 7.11 (dd, J = 2.8, 5.8 Hz, 1H), 3.59 (s, 2H), 3.03 (br s, 4H), 2.75–2.58 (m, 7H), 1.91 (s, 2H). 2-Methyl-5-(1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)­phenethyl)­piperidin-4-yl)­quinoline (49c). 47c (82.7 mg, 1.0 equiv, 0.20 mmol), B2Pin2 (61.6 mg, 1.2 equiv, 0.24 mmol), potassium acetate (39.6 mg, 2.0 equiv, 0.40 mmol), and PdCl2(dppf)–CH2Cl2 (8.25 mg, 0.05 equiv, 0.01 mmol) were dissolved in anhydrous previously degassed 1,4-Dioxane (3.0 mL). The reaction mixture was placed at 80 °C and stirred overnight for 1 h. The reaction mixture was treated with water (10 mL), extracted with EA (3 × 20 mL), washed with brine (10 mL), and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure, and the crude was purified by column chromatography on silica gel eluting with CH to CH/EtOAc 0–100% (Column IloK 12 g, 24 CV) delivering 69.9 mg of product 49c (69%) as a yellow sticky oil. LCMS [M + H]+ 457, UV 91%; 1H NMR (400 MHz, DMSO-d 6) δ = 8.49 (d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.65 (dd, J = 7.3, 8.3 Hz, 1H), 7.56 (s, 1H), 7.51 (td, J = 1.3, 7.3 Hz, 1H), 7.46–7.42 (m, 2H), 7.40 (td, J = 1.6, 7.6 Hz, 1H), 7.35–7.27 (m, 1H), 3.28 (br d, J = 4.3 Hz, 1H), 3.11 (br d, J = 11.3 Hz, 2H), 2.80 (dd, J = 6.6, 9.1 Hz, 2H), 2.65 (s, 3H), 2.59 (dd, J = 6.5, 9.3 Hz, 2H), 2.27 (dt, J = 2.8, 11.3 Hz, 2H), 1.87–1.72 (m, 4H), 1.30 (s, 12H). N -Methyl-6-(3-(2-(4-(2-methylquinolin-5-yl)­piperazin-1-yl)­ethyl)­phenyl)­picolinamide (41c). 49a (40 mg, 1.0 equiv, 0.087 mmol), 40 (29.8 mg, 1.3 equiv, 0.11 mmol), K2CO3 (24.2 mg, 2.0 equiv, 0.17 mmol), and PdCl2(dppf)–CH2Cl2 (7.14 mg, 0.1 equiv, 0.087 mmol) were dissolved under nitrogen in previously degassed 1,4-dioxane (1.0 mL) and water (0.5 mL). The reaction was stirred under heating to 80 °C for 2 h. The reaction mixture was treated with water (10 mL), extracted with EA (3 × 20 mL), washed with brine (10 mL), and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and the crude was purified by preparative HPLC. The fraction containing the product was collected, and the solvents were evaporated in vacuo to yield 17 mg of 41c (42%); LCMS showed the desired product [M + H]+ = 466.4 at Rt = 0.66 min with a 100% purity by UV (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 8.85 (q, J = 4.3 Hz, 1H), 8.36 (d, J = 8.5 Hz, 1H), 8.24–8.11 (m, 3H), 8.06 (t, J = 7.8 Hz, 1H), 8.00–7.94 (m, 1H), 7.67–7.54 (m, 2H), 7.50–7.43 (m, 1H), 7.40 (d, J = 8.8 Hz, 2H), 7.12 (dd, J = 2.6, 5.9 Hz, 1H), 3.06 (br s, 4H), 2.99–2.92 (m, 2H), 2.91 (d, J = 5.0 Hz, 3H), 2.84–2.70 (m, 5H), 2.64 (s, 3H); 13C NMR (101 MHz, DMSO-d 6) δ = 164.87, 158.74, 155.57, 150.40, 150.04, 149.08, 141.54, 139.16, 138.06, 132.45, 130.37, 129.80, 129.15, 127.83, 125.21, 123.74, 123.03, 121.78, 121.62, 120.72, 114.45, 60.15, 53.49, 53.34, 33.32, 26.59, 25.15. N -Methyl-6-(3-((4-(2-methylquinolin-5-yl)­piperazin-1-yl)­methyl)­phenyl)­picolinamide (41d). 49b (65.0 mg, 1.0 equiv, 0.18 mmol), 40 (61.3 mg, 1.3 equiv, 0.23 mmol), K2CO3 (49.7 mg, 2.0 equiv, 0.36 mmol), and PdCl2(dppf)–CH2Cl2 (14.7 mg, 0.1 equiv, 0.018 mmol) were dissolved under nitrogen in previously degassed 1,4-dioxane (1.0 mL) and water (0.5 mL). The reaction was stirred under heating to 80 °C for 1 h. The reaction mixture was treated with water (10 mL), extracted with EA (3 × 20 mL), washed with brine (10 mL), and dried over anhydrous Na2SO4. The solvent was removed, and the crude was dissolved in MeOH/DMSO (4/1) and purified by preparative HPLC. The fractions containing the product were collected, and the solvents were evaporated in vacuo to yield 39 mg (48%) of product 41d; LCMS showed the desired product [M + H]+ = 452.4 at Rt = 0.63 min, 100% purity by UV (Acquity UPLC BEH C18; 5–100%, Acid, 2 min); 1H NMR (400 MHz, DMSO-d 6) δ = 8.85 (q, J = 4.3 Hz, 1H), 8.34 (d, J = 8.8 Hz, 1H), 8.25 (br d, J = 6.3 Hz, 1H), 8.22–8.15 (m, 2H), 8.07 (t, J = 7.8 Hz, 1H), 8.02–7.95 (m, 1H), 7.65–7.56 (m, 2H), 7.55–7.45 (m, 2H), 7.38 (d, J = 8.8 Hz, 1H), 7.12 (dd, J = 2.8, 5.8 Hz, 1H), 3.74 (br s, 2H), 3.06 (br s, 4H), 2.91 (d, J = 4.8 Hz, 3H), 2.81–2.66 (m, 4H), 2.63 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ = 164.87, 158.73, 155.47, 150.47, 150.01, 149.05, 139.23, 138.09, 132.43, 130.64, 129.78, 129.19, 128.04, 126.40, 123.75, 123.09, 121.77, 121.63, 120.80, 114.49, 62.51, 53.41, 53.32, 26.59, 25.14. N -Methyl-6-(3-(2-(4-(2-methylquinolin-5-yl)­piperidin-1-yl)­ethyl)­phenyl)­picolinamide (41h). 49c (70 mg, 1.0 equiv, 0.15 mmol), 40 (52.2 mg, 1.3 equiv, 0.2 mmol), K2CO3 (42.4 mg, 2.0 equiv, 0.31 mmol), and PdCl2(dppf)–CH2Cl2 (12.5 mg, 0.1 equiv, 0.015 mmol) were dissolved under nitrogen in previously degassed 1,4-dioxane (1.0 mL) and water (0.5 mL). The reaction was stirred and heated at 80 °C for 1 h. The reaction mixture was treated with water (10 mL), extracted with EA (3 × 20 mL), washed with brine (10 mL), and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and the crude was dissolved in 1.8 mL of MeOH/DMSO (3/1) and purified by preparative HPLC. The fractions containing product were collected with DCM/MeOH (1/1), and the solvents were evaporated in vacuo to yield 38.5 mg of 41h (54%). LCMS showed the desired product [M + H]+ = 465.4; UV = 100%, Rt = 1.47 min (XBridge C18 3.5 μm; 4.6 × 50 mm at 40 °C; 50–100% (Water 5 mM ammonium bicarbonate/Acetonitrile), 3 min at 1 mL/min); 1H NMR (400 MHz, DMSO-d6) δ = 8.85 (q, J = 4.6 Hz, 1H), 8.49 (d, J = 8.8 Hz, 1H), 8.20–8.12 (m, 3H), 8.06 (t, J = 7.8 Hz, 1H), 7.99–7.96 (m, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.66 (dd, J = 7.4, 8.4 Hz, 1H), 7.48–7.41 (m, 3H), 7.41–7.34 (m, 1H), 3.32–3.27 (m, 1H), 3.15 (br d, J = 11.3 Hz, 2H), 2.94 (br d, J = 7.3 Hz, 2H), 2.90 (d, J = 4.8 Hz, 3H), 2.69 (dd, J = 6.5, 9.3 Hz, 2H), 2.65 (s, 3H), 2.30 (dt, J = 2.8, 11.4 Hz, 2H), 1.93–1.71 (m, 4H); 13C NMR (101 MHz, DMSO-d6) δ = 164.87, 158.46, 155.59, 150.40, 148.29, 143.27, 141.72, 139.14, 138.04, 132.25, 130.35, 129.57, 129.13, 127.82, 127.08, 125.17, 124.60, 123.03, 122.37, 122.22, 120.72, 60.57, 54.24, 37.01, 33.56, 33.45, 26.59, 25.09. Compounds 41e, 41f, 41g, 41i, 41j, and 41k were available and evaluated from the GSK library. LCMS and purity data are included in the Supporting Information. Supplementary Material